- Conditions: Bone Metastases; Castrate-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: cabozantinib; Other: laboratory biomarker analysis; Procedure: magnetic resonance imaging
Sponsors: University of Chicago; University of Chicago; NorthShore University Health System
Recruiting - verified May 2012 - Conditions: Sarcoma; Solid Tumors; Pulmonary Metastases; Lung Metastases; Osteosarcomas; Ewing Sarcoma
Interventions: Drug: Aerosol IL-2; Procedure: Symptom Assessment
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Shannon Wilkes Foundation
Not yet recruiting - verified May 2012 - Conditions: Neuroblastoma; Ewing's Sarcoma; Wilm's Tumor; Retinoblastoma; Glioma
Intervention: Drug: racotumomab
Sponsors: Laboratorio Elea S.A.C.I.F. y A.; Laboratorio Elea S.A.C.I.F. y A.; Ministry of Science and Technology; Netherlands: Ministry of Health, Welfare and Sports
Recruiting - verified May 2012 - Condition: Bone Metastasis
Intervention: Device: MR-HIFU treatment for pain palliation of bone metastases
Sponsors: Philips Healthcare; Philips Healthcare
Not yet recruiting - verified April 2012 - Conditions: Adult Rhabdomyosarcoma; Lung Metastases; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Stage IV Adult Soft Tissue Sarcoma; Stage IV Wilms Tumor; Stage V Wilms Tumor; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: intensity-modulated radiation therapy
Sponsors: Children's Memorial Hospital; Children's Memorial Hospital; Northwestern University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Ewing Family of Tumors, Rhabdomyosarcoma
Intervention: Drug: Lipegfilgrastim
Sponsors: Teva Pharmaceutical Industries; Merckle GmbH
Not yet recruiting - verified May 2012 - Condition: Ewing's Sarcoma
Intervention: Drug: Olaparib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified April 2012 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Meningioma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Tumor; Adult Craniopharyngioma; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Myxopapillary Ependymoma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pilocytic Astrocytoma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Pineocytoma; Adult Subependymal Giant Cell Astrocytoma; Adult Subependymoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Meningeal Melanocytoma; Nonmalignant Neoplasm; Recurrent Adult Brain Tumor; Tumors Metastatic to Brain
Interventions: Drug: pioglitazone hydrochloride; Other: laboratory biomarker analysis; Radiation: external beam radiation therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Myeloid Leukaemia; Acute Lymphoblastic Leukaemia; Myelodysplastic Syndrome; Chronic Myeloid Leukaemia; Chronic Lymphocytic Leukaemia; Acquired Bone Marrow Failure Syndromes
Interventions: Procedure: Reduced intensity haplodentical stem cell transplant; Procedure: Myeloablative haploidentical stem cell transplant
Sponsors: University College, London; University College, London; Leukaemia Lymphoma Research
Not yet recruiting - verified May 2012 - Conditions: Breast Cancer; Musculoskeletal Complications; Pain; Therapy-related Toxicity
Interventions: Drug: duloxetine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Conditions: Myeloid Malignancy; Bone Marrow Failure Syndrome; Transfusion-dependent Red Blood Cell (RBC) Defect; Congenital Immunodeficiency; Metabolic Disease; Severe Immune Dysregulation
Interventions: Drug: Alemtuzumab; Drug: Busulfan; Drug: Fludarabine; Drug: Clofarabine
Sponsors: University of California, San Francisco; Christopher Dvorak
Not yet recruiting - verified May 2012 - Conditions: Glioma; Neurofibromatosis Type 1
Intervention:
Sponsors: Children's Memorial Hospital; Children's Memorial Hospital
Recruiting - verified May 2012 - Conditions: Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Burkitt's Lymphoma; Follicular Lymphoma; Hodgkin Lymphoma; Mantle Cell Lymphoma
Interventions: Drug: Biological/Vaccine: Haploidentical BMT; Drug: Double Cord Blood Transplantation
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Not yet recruiting - verified May 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cytomegalovirus Infection; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Isolated Plasmacytoma of Bone; Monoclonal Gammopathy of Undetermined Significance; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Primary Myelofibrosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Multiple Myeloma; Stage I Small Lymphocytic Lymphoma; Stage IA Mycosis Fungoides/Sezary Syndrome; Stage IB Mycosis Fungoides/Sezary Syndrome; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage IIA Mycosis Fungoides/Sezary Syndrome; Stage IIB Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IIIA Mycosis Fungoides/Sezary Syndrome; Stage IIIB Mycosis Fungoides/Sezary Syndrome; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Small Lymphocytic Lymphoma; Stage IVA Mycosis Fungoides/Sezary Syndrome; Stage IVB Mycosis Fungoides/Sezary Syndrome; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia
Interventions: Biological: tetanus-CMV fusion peptide vaccine; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Conditions: Non-Hodgkin's Lymphoma; Hodgkin Lymphoma; Multiple Myeloma; Chronic Myelogenous Leukemia
Intervention: Biological: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012 - Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: Azacitidine
Sponsors: Celgene Corporation; Celgene Corporation; PRA International
Not yet recruiting - verified May 2012 - Condition: Neoplasms, Hematologic
Interventions: Drug: 200 mg LY2784544; Drug: 400 mg LY2784544; Drug: 600 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Conditions: Acute Leukemia; Chronic Leukemia; Myelodysplastic Syndrome; Non-Hodgkins Lymphoma
Intervention: Drug: CD34+ progenitors on the Clinimacs device
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012 - Condition: Chronic Myeloid Leukemia
Intervention: Other: Stopping treatment with TKI
Sponsors: European LeukemiaNet; European LeukemiaNet
Not yet recruiting - verified May 2012 - Conditions: Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Acute Myeloid Leukemia
Intervention: Other: non interventional
Sponsors: Arbeitsgemeinschaft medikamentoese Tumortherapie; Arbeitsgemeinschaft medikamentoese Tumortherapie
Recruiting - verified May 2012 - Conditions: Axial and Peripheral Spondyloarthritis; Rheumatoid Arthritis
Interventions: Drug: administration of Cimzia®; Drug: Immunoscintigraphy with radiolabeled Cimzia®.
Sponsors: University Hospital, Ghent; University Hospital, Ghent; UCB Pharma SA
Not yet recruiting - verified May 2012 - Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Imatinib; Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012 - Condition: Multiple Myeloma
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified April 2012 - Conditions: Chronic Myeloid Leukemia (CML); Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Intervention: Drug: ponatinib
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Available - verified May 2012 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Decitabine; Drug: Vorinostat; Biological: Interleukin-2; Other: Natural killer (NK) cells
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified May 2012 - Conditions: Malignant Peripheral Nerve Sheath Tumors of the Spine; Neurofibroma
Interventions: Radiation: Proton Therapy; Radiation: Proton Therapy
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Conditions: Mucopolysaccharidosis I; Mucopolysaccharidosis VI; Adrenoleukodystrophy; Niemann-Pick Disease; Metachromatic Leukodystrophy; Wolman Disease; Krabbe's Disease; Gaucher's Disease; Fucosidosis; Batten Disease; Severe Aplastic Anemia; Diamond-Blackfan Anemia; Amegakaryocytic Thrombocytopenia; Myelodysplastic Syndrome; Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia
Intervention: Drug: Human Placental Derived Stem Cell
Sponsors: New York Medical College; New York Medical College
Not yet recruiting - verified April 2012 - Condition: Bone Cancer
Interventions: Radiation: fluorine F 18 sodium fluoride; Procedure: positron emission tomography/computed tomography
Sponsors: Stanford University; Stanford University
Not yet recruiting - verified February 2012 - Conditions: Myelodysplastic Syndrome; MDS
Interventions: Drug: rigosertib sodium; Drug: rigosertib sodium
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.
Recruiting - verified May 2012 - Condition: Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia
Intervention: Drug: nilotinib
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Multiple Myeloma; Smoldering Multiple Myeloma; Monoclonal Gammopathy of Undetermined Significance
Intervention: Drug: Fluciclatide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Genetic: gene expression analysis; Other: flow cytometry; Other: fluorescence activated cell sorting; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Acute Myeloid Leucemia
Intervention:
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Not yet recruiting - verified April 2012 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib mesylate
Sponsors: University of Milano Bicocca; University of Milano Bicocca
Recruiting - verified April 2012 - Conditions: Acromegaly; Nonfunctioning Pituitary Tumor
Intervention:
Sponsors: Emory University; Emory University
Recruiting - verified March 2012 - Conditions: Leukemia; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Diseases; Non-Hodgkins Lymphoma; Hodgkins Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome
Interventions: Drug: Fludarabine monophosphate; Drug: Busulfan; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Hemangiopericytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Childhood Alveolar Soft-part Sarcoma; Childhood Angiosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Childhood Epithelioid Hemangioendothelioma; Childhood Epithelioid Sarcoma; Childhood Fibrosarcoma; Childhood Leiomyosarcoma; Childhood Liposarcoma; Childhood Malignant Hemangiopericytoma; Childhood Malignant Mesenchymoma; Childhood Neurofibrosarcoma; Childhood Synovial Sarcoma; Dermatofibrosarcoma Protuberans; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: gemcitabine hydrochloride; Drug: pazopanib hydrochloride; Other: placebo; Other: laboratory biomarker analysis
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); GlaxoSmithKline
Recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Procedure: management of therapy complications; Procedure: musculoskeletal complications management/prevention
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified May 2012 - Condition: Leukemia
Intervention: Drug: Ponatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ariad Pharmaceuticals
Recruiting - verified April 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: Oral azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Not yet recruiting - verified April 2012 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: tosedostat; Drug: cytarabine; Drug: decitabine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Chronic Myeloid Leukemia; Imatinib; Complete Molecular Response
Intervention: Behavioral: Imatinib treatment discontinuing
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital; Ministry of Health & Welfare, Korea
Recruiting - verified March 2012 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsConditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Not yet recruiting - verified March 2012 - Conditions: Myelodysplastic Syndrome (MDS); Hematologic Neoplasms; Hematologic Diseases; Severe Aplastic Anemia
Intervention: Procedure: Cord Blood Transplant
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Conditions: Brain and Central Nervous System Tumors; Neurofibromatosis Type 1
Intervention: Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Basal Cell Nevus Syndrome; Gorlin's Syndrome
Interventions: Drug: GDC-0449; Procedure: Aminolevulinic acid %20 topical solution + blue light
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland; Genentech
Not yet recruiting - verified March 2012 - Condition: Prostatic Neoplasms
Interventions: Drug: BAY88-8223 (Radium-223 chloride); Drug: BAY88-8223 (Radium-223 chloride)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Conditions: Myelodysplastic Syndrome; Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine; Drug: azacitidine + lenalidomide
Sponsors: Nordic MDS Group; Nordic MDS Group
Recruiting - verified March 2012 - Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 chloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified April 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Blastic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; de Novo Myelodysplastic Syndromes; Noncontiguous Stage II Adult Burkitt Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Stage I Adult Burkitt Lymphoma; Stage III Adult Burkitt Lymphoma; Stage IV Adult Burkitt Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: rasburicase; Drug: allopurinol; Drug: rasburicase
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012 - Conditions: Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: eltrombopag olamine; Procedure: standard follow-up care
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified May 2012 - Condition: Breast Cancer Recurrent
Intervention: Radiation: Dual-time PET/CT (low-dose)
Sponsors: Odense University Hospital; Odense University Hospital
Recruiting - verified March 2012 - Conditions: Philadelphia Chromosome Positive (Ph+) Leukemias; Chronic Myeloid Leukemia
Intervention: Drug: Ponatinib
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; Ariad Pharmaceuticals
Available - verified March 2012 - Conditions: Rhabdomyosarcoma and Other Soft Tissue Sarcomas; Ewing's Sarcoma Family of Tumors; Osteosarcoma; Neuroblastoma; Brain Tumors
Interventions: Drug: sorafenib; Drug: irinotecan
Sponsors: Children's Research Institute; Children's Research Institute
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan); Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan); Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12); Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
Sponsors: University of Iowa; University of Iowa; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Acute Myeloid Leukemia; High-risk Myelodysplastic Syndrome
Interventions: Drug: PF-04449913; Drug: LDAC; Drug: PF-04449913; Drug: Decitabine; Drug: PF-04449913; Drug: Daunorubicin; Drug: cytarabine
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Azacytidine; Drug: GM-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Progressive Hairy Cell Leukemia, Initial Treatment; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Hairy Cell Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: sirolimus; Drug: tacrolimus; Biological: rituximab; Biological: anti-thymocyte globulin; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Multiple Myeloma
Intervention: Drug: G-CSF and Bortezomib
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012 - Conditions: Hematologic Malignancy; Leukemia; Acute Lymphoblastic Leukemia; ALL; Acute Myelogenous Leukemia; AML; Chronic Lymphocytic Leukemia; CLL; Lymphoma; Hodgkin's Lymphoma; Non-hodgkin's Lymphoma; Myeloma
Interventions: Radiation: Total Body Irradiation (TBI); Biological: Donor Lymphocyte Infusion (DLI); Drug: Cyclophosphamide (CY); Drug: Tacrolimus; Drug: Mycophenolate Mofetil (MMF); Biological: Hematopoietic Stem Cell Transplant (HSCT)
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified April 2012 - Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Intervention: Drug: TevaGastrim
Sponsors: Sheba Medical Center; Sheba Medical Center
Recruiting - verified February 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Congenital Amegakaryocytic Thrombocytopenia; Diamond-Blackfan Anemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Paroxysmal Nocturnal Hemoglobinuria; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Severe Combined Immunodeficiency; Severe Congenital Neutropenia; Shwachman-Diamond Syndrome; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia; Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Drug: methotrexate; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: trebananib; Drug: cytarabine; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Low Risk Metastatic Gestational Trophoblastic Tumor; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Gestational Trophoblastic Tumor; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: atorvastatin calcium; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Childhood Acute Lymphoblastic Leukemia; Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies; Ewing Sarcoma; Vomiting in Infants and/or Children; Osteosarcoma
Interventions: Procedure: electroacupuncture therapy; Other: questionnaire administration; Procedure: electroacupuncture therapy
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Previously Treated Myelodysplastic Syndromes; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: atorvastatin calcium; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Oncogenic Osteomalacia; Mesenchymal Tumor
Intervention: Drug: 68Ga-DOTATATE
Sponsors: Peking Union Medical College Hospital; Peking Union Medical College Hospital
Recruiting - verified January 2011 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting - verified February 2012 - Condition: Transplantation for Hematologic Malignancies
Interventions: Procedure: G-PB Transplant; Procedure: G-BM Transplant
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Recruiting - verified February 2012 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Stanford University; Robert Lowsky; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Neuroblastoma; Sarcoma
Intervention: Drug: Cyclophosphamide, Topotecan, and Bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Children's Mercy Hospital Kansas City; Penn State University; University of Colorado Health Sciences Center and The Children's Hospital; Johns Hopkins Medical Center Sidney Kimmel Comprehensive Cancer Center; Phoenix Children's Hospital Center for Cancer & Blood Disorders; Alberta Children's Hospital; MD Anderson Cancer Center Orlando; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Conditions: Myelodysplastic Syndrome (MDS); Chronic Myelogenous Leukemia; Acute Lymphoblastic Leukemia; CML (Chronic Myelogenous Leukemia; CLL (Chronic Lymphocytic Leukemia); Acute Myeloid Leukemia (AML)
Intervention: Procedure: Stem Cell Transplantation
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011 - Conditions: Leukemia; Lymphoma; Myeloma; Myeloproliferative Diseases
Interventions: Drug: Fludarabine; Drug: Melphalan; Drug: Alemtuzumab; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF; Procedure: Low Dose Donor T-Cells; Procedure: High Dose Donor T-Cells
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
Interventions: Drug: oral azacitidine; Drug: oral azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012 - Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified April 2012 - Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: CPI-613
Sponsors: Cornerstone Pharmaceuticals, Inc.; Cornerstone Pharmaceuticals, Inc.
Not yet recruiting - verified February 2012 - Conditions: Brain Tumor; Spinal Stenosis; Cerebral Artery Anuerysm
Intervention: Drug: Heparin
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital
Recruiting - verified January 2012 - Conditions: Acute Leukemia; Myelodysplastic Syndrome; Solid Tumors
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Radiation: Total body irradiation; Drug: Fludarabine; Drug: cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate mofetil; Drug: Rituximab
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified January 2012 - Conditions: Infection; Bone Neoplasms
Intervention: Procedure: Prophylactic Cefazolin Antibiotic Regimen
Sponsors: McMaster University; Michelle Ghert
Not yet recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Cladribine; Drug: Cytarabine; Drug: Decitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention: Device: performance of PET/CT and whole-body MRI
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified December 2011 - Conditions: Leukemia; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Bone Marrow Diseases; Hematologic Diseases
Interventions: Drug: Imatinib; Drug: Radotinib
Sponsors: Il-Yang Pharm. Co., Ltd.; Il-Yang Pharm. Co., Ltd.
Recruiting - verified January 2012 - Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Burkitts Leukemia/Lymphoma; Chronic Myelogenous Leukemia
Interventions: Drug: CLAG-M; Drug: CLAG-M
Sponsors: New York Medical College; New York Medical College
Recruiting - verified January 2012 - Conditions: Bone Marrow Transplant Infection; Infection in Marrow Transplant Recipients; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Pneumonia; Cancer; Acute Leukemia
Interventions: Drug: Ribavirin; Drug: Ribavirin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012 - Condition: Bone Metastases
Intervention: Other: blood sampling, the SF-36 questionnaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Naval Medical Research Center
Recruiting - verified November 2011 - Conditions: Hodgkin Disease; Lymphoma, Non-Hodgkin
Intervention: Other: Database
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Recruiting - verified December 2011 - Conditions: Leukemia; Lymphoma
Interventions: Procedure: Hematopoietic stem-cell transplant; Genetic: CD19-specific T cell Infusion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Cancer
Intervention:
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Not yet recruiting - verified January 2012 - Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Decitabine; Drug: Decitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Osteosarcoma
Interventions: Drug: 5 drugs based chemotherapy; Other: 3 drugs based chemotherapy
Sponsors: Italian Sarcoma Group; Italian Sarcoma Group
Recruiting - verified October 2011 - Conditions: Pain; Neoplasm Metastasis
Intervention: Procedure: Cryoablation
Sponsors: Galil Medical; Galil Medical
Recruiting - verified April 2012 - Conditions: Pain; Neoplasm Metastasis
Interventions: Procedure: Cryoablation; Procedure: Radiation
Sponsors: Galil Medical; Galil Medical
Not yet recruiting - verified April 2012 - Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Myelodysplastic Syndrome
Interventions: Drug: atorvastatin; Drug: Tacrolimus; Drug: methotrexate
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: MDS
Intervention: Drug: KRN321
Sponsors: Kyowa Hakko Kirin Company, Limited; Kyowa Hakko Kirin Company, Limited
Recruiting - verified December 2011 - Conditions: Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Non Hodgkin Lymphoma; Hemophagocytic Lymphohistiocytosis; Familial Hemophagocytic Lymphohistiocytosis; Hemophagocytic Syndrome; Epstein Barr Virus Infection; X-linked Lymphoproliferative Disease
Intervention: Genetic: Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene and AP1903
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Recruiting - verified April 2012 - Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Interventions: Drug: Azacitidine; Other: DLI
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified March 2012 - Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab; Radiation: Stereotactic Body Radiation Therapy
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified December 2011 - Condition: Prostate Cancer
Intervention: Procedure: Sodium Flouride (NaF) Positron Emission Tomograpy/Computed Tomography (PET/CT) imaging
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified January 2012 - Condition: Chronic Myeloid Leukemia
Interventions: Behavioral: no access to eMedonline; Behavioral: eMedonline access
Sponsors: Rex Cancer Center, Raleigh, NC; Rex Cancer Center, Raleigh, NC; Northwestern University
Recruiting - verified December 2011 - Conditions: Obesity; Overweight; Craniopharyngioma
Intervention: Drug: Exenatide
Sponsors: Vanderbilt University; Vanderbilt University
Not yet recruiting - verified November 2011 - Conditions: Acute Myeloid Leukemia; Acute Leukemia; Chronic Myelogenous Leukemia; Malignant Lymphoma; Hodgkin's Disease; Multiple Myeloma; Lymphocytic Leukemia; Myeloproliferative Disorder; Polycythemia Vera; Myelofibrosis; Aplastic Anemia
Interventions: Drug: fludarabine/busulfan; Drug: fludarabine/ melphalan
Sponsors: University of Illinois; University of Illinois
Recruiting - verified September 2011 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Interpheron alpha
Sponsors: Università degli Studi di Brescia; Università degli Studi di Brescia
Recruiting - verified December 2011 - Conditions: Myelodysplastic Syndromes (MDS); Acute Myeloid Leukaemia (AML)
Intervention: Drug: Azacitidine and eltrombopag
Sponsors: Peter MacCallum Cancer Centre, Australia; Peter MacCallum Cancer Centre, Australia; GlaxoSmithKline; Celgene Corporation
Recruiting - verified December 2011 - Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Hodgkins Disease; Non-Hodgkins Lymphoma; Aplastic Anemia; Multiple Myeloma; Myelodysplastic Syndrome
Interventions: Drug: Busulfan; Drug: Clofarabine; Drug: Fludarabine; Drug: Melphalan; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine
Sponsors: Texas Oncology Cancer Center; Texas Oncology Cancer Center
Recruiting - verified December 2011 - Conditions: Blood And Marrow Transplantation; Leukemia; Lymphoma; Transplantation Infection; Transplantation, Bone Marrow
Interventions: Drug: Melphalan; Drug: Thiotepa; Drug: Fludarabine; Drug: Mycophenolate mofetil; Drug: Tacrolimus; Procedure: Cord Blood Infusion; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified April 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: ARRY-614, p38/Tie2 inhibitor; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified March 2012 - Conditions: Acute Myelocytic Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia; Marginal Zone Lymphoma; Follicular Lymphomas; Large-cell Lymphoma; Lymphoblastic Lymphoma; Burkitt's Lymphoma; High Grade Lymphomas; Mantle-cell Lymphoma; Lymphoplasmacytic Lymphoma
Intervention: Biological: HSC835
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified November 2011 - Conditions: Acute Leukemia in Remission; Myelodysplastic Syndromes; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myeloid, Accelerated-Phase
Interventions: Drug: Sirolimus; Drug: Tacrolimus
Sponsors: The Korean Society of Blood and Marrow Transplantation; The Korean Society of Blood and Marrow Transplantation; Asan Medical Center; Chonnam National University Hospital; Gachon University Gil Medical Center; Korea University Guro Hospital; National Cancer Center, Korea; Pusan National University Hospital; Samsung Medical Center; Severance Hospital; Seoul St. Mary's Hospital; Soonchunhyang University Hospital
Not yet recruiting - verified December 2011 - Conditions: Disorder Related to Bone Marrow Transplantation; Leukemia; Transplantation Infection
Interventions: Drug: Fludarabine; Drug: Clofarabine; Drug: Busulfan; Drug: Thymoglobulin; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Myelodysplastic Syndrome; Thrombocytopenia
Intervention: Drug: Eltrombopag
Sponsors: Nordic MDS Group; Nordic MDS Group; GlaxoSmithKline
Recruiting - verified November 2011 - Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified February 2012 - Conditions: Acute Leukemia; Chronic Leukemia; Severe Aplastic Anemia
Intervention: Drug: Fludarabine
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Korea Food and Drug Administration
Recruiting - verified March 2012 - Conditions: Adult Acute Lymphoblastic Leukemia; Adult Acute Myeloid Leukemia; Adult Burkitt Lymphoma; Adult Diffuse Large Cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Hodgkin Lymphoma; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Breast Cancer; Chronic Eosinophilic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Cutaneous T-cell Non-Hodgkin Lymphoma; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Malignant Testicular Germ Cell Tumor; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Multiple Myeloma; Mycosis Fungoides/Sezary Syndrome; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neutropenia; Nodal Marginal Zone B-cell Lymphoma; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Primary Myelofibrosis; Prolymphocytic Leukemia; Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma
Intervention: Drug: cefepime hydrochloride
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Montefiore Medical Center; State University of New York - Downstate Medical Center; NYU MEDICAL CENTER; University of Rochester; Weill Medical College of Cornell University; Stamford Hospital
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: Azacitidine (AZA); Drug: Tyrosine kinase inhibitor (TKI); Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Not yet recruiting - verified April 2012 - Conditions: Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Refractory Anemia With Excess of Blasts (RAEB)
Intervention:
Sponsors: Skyline Diagnostics BV; Skyline Diagnostics BV; Skyline Diagnostics BV is the European based Sponsor/ Manufacturer and Myraqa, Inc is the US Sponsor.
Recruiting - verified February 2012 - Conditions: Acute Myeloid Leukemia; Advanced Myelodysplastic Syndrome
Interventions: Drug: Panobinostat; Drug: Cytarabine; Drug: Daunorubicin
Sponsors: University of California, San Francisco; C. Babis Andreadis; University of California, San Francisco; Novartis
Recruiting - verified March 2012 - Condition: Bone Metastases
Interventions: Radiation: Conventional Radiotherapy; Radiation: Biological image-guided radiotherapy with conventional dose.; Radiation: Biological image-guided SBRT with dose-escalation.
Sponsors: University Hospital, Ghent; University Hospital, Ghent
Not yet recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: Lapatinib; Radiation: Radiation therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified January 2012 - Condition: Prostate Cancer Metastatic
Intervention: Drug: Cabozantinib
Sponsors: University of Michigan Cancer Center; David C Smith; Exelixis
Recruiting - verified March 2012 - Conditions: Cardiovascular Diseases; Cancer
Interventions: Dietary Supplement: Vitamin D3; Dietary Supplement: Vitamin D3; Dietary Supplement: Placebo
Sponsors: University of Eastern Finland; University of Eastern Finland; Academy of Finland; Juho Vainio Foundation; Finnish Foundation for Cardiovascular Research
Not yet recruiting - verified October 2011 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab + BSC; Drug: Placebo + BSC
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Condition: Chronic Phase CML
Interventions: Behavioral: no access to eMedonline; Behavioral: eMedonline access
Sponsors: Rex Cancer Center, Raleigh, NC; Rex Cancer Center, Raleigh, NC; Northwestern University
Recruiting - verified December 2011 - Condition: Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib + LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: HIV Infections; Central Nervous System Neoplasms; Neurofibromatosis 1
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Promyelocytic Leukemia (M3); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia
Intervention: Drug: bortezomib
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib and Cyclosporine
Sponsors: University of Colorado, Denver; University of Colorado, Denver; National Cancer Institute and Leukemia and Lymphoma Society
Recruiting - verified October 2011 - Conditions: Leukemia, Myelomonocytic, Chronic; Leukemia-Lymphoma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: ezatiostat hydrochloride (Telintra®)
Sponsors: Telik; Telik
Recruiting - verified October 2011 - Conditions: Multiple Myeloma; Allogeneic Transplantation
Intervention:
Sponsors: Azienda Ospedaliera San Giovanni Battista; Azienda Ospedaliera San Giovanni Battista
Not yet recruiting - verified September 2011 - Condition: Breast Cancer
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Exelixis
Recruiting - verified January 2012 - Condition: Craniopharyngioma
Interventions: Procedure: Radical Surgery or limited surgery and proton therapy; Radiation: Proton Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified March 2012 - Conditions: Bone Metastases; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: hydroxychloroquine; Radiation: radiation therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia
Interventions: Drug: Panobinostat; Drug: Panobinostat
Sponsors: Johann Wolfgang Goethe University Hospitals; Johann Wolfgang Goethe University Hospitals
Recruiting - verified December 2011 - Conditions: Leukemia; Myeloproliferative Diseases
Interventions: Drug: Clofarabine; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Genetic: proteomic profiling; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: medical chart review; Other: single cell network profile assay
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified October 2011 - Conditions: Leukemia; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS)
Interventions: Drug: Azacitidine; Drug: Lenalidomide
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified September 2011 - Condition: Vertebral Bony Metastases
Intervention: Other: exercise
Sponsors: University of Heidelberg; University of Heidelberg; Dept of Radiation Oncology, University of Heidelberg, Germany
Not yet recruiting - verified August 2011 - Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Intervention: Drug: Lenalidomide
Sponsors: University of California, Davis; University of California, Davis; Celgene Corporation
Not yet recruiting - verified April 2012 - Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention:
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified February 2012 - Conditions: Adult Spinal Cord Neoplasm; Spinal Bone Metastases; Spinal Cord Compression
Interventions: Procedure: musculoskeletal complications management/prevention; Procedure: bone graft; Procedure: quality-of-life assessment; Other: questionnaire administration
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelogenous Leukemia, Chronic, Chronic Phase
Intervention:
Sponsors: Kanto CML Study Group; Kanto CML Study Group
Recruiting - verified November 2011 - Condition: Thrombocytopaenia
Interventions: Drug: eltrombopag; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Myeloid Leukemia in Remission; Adult Erythroleukemia (M6a); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Pure Erythroid Leukemia (M6b); Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Erythroleukemia (M6); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Philadelphia Chromosome Negative Chronic Myelogenous Leukemia; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage III Multiple Myeloma; Testicular Lymphoma; Waldenström Macroglobulinemia
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation; Drug: fludarabine phosphate; Drug: busulfan; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Carcinoid Syndrome
Intervention:
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; NIHR Biomedical Research Unit for Musculoskeletal Disease
Recruiting - verified September 2011 - Condition: Leukemia
Intervention: Drug: Eltrombopag
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: cyclosporine; Drug: dasatinib; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Bone Metabolism Biomarkers; Bone Mineral Density; Physical Fitness
Interventions: Drug: Vitamin D3; Behavioral: Home-Based Exercise
Sponsors: University of Rochester; University of Rochester
Not yet recruiting - verified August 2011 - Conditions: Acute Myeloid Leukaemia; Myelodysplasia
Interventions: Drug: Clofarabine; Drug: Clofarabine
Sponsors: Southampton University Hospitals NHS Trust; Southampton University Hospitals NHS Trust; Genzyme
Recruiting - verified August 2011 - Conditions: Myelofibrosis; Gaucher Disease; Pulmonary Fibrosis; Hermansky-Pudlak Syndrome (HPS); Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2011 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: tacrolimus; Biological: anti-thymocyte globulin; Other: laboratory biomarker analysis; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute
Recruiting - verified April 2012 - Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: ezatiostat hydrochloride (Telintra®)
Sponsors: Telik; Telik
Recruiting - verified August 2011 - Conditions: Primary Myelofibrosis; Post-Polycythemic Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: NS-018
Sponsors: NS Pharma, Inc.; NS Pharma, Inc.
Recruiting - verified April 2012 - Condition: Myelodysplastic Syndromes
Interventions: Drug: CHG regimen; Drug: 5-aza-deoxycytidine
Sponsors: Shanghai Sixth People's Hospital; Xiao Li
Not yet recruiting - verified September 2011 - Conditions: Neurofibromatosis Type 1; Plexiform Neurofibroma; Neurofibromatoses
Intervention: Drug: RAD001: Everolimus
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Novartis
Recruiting - verified June 2011 - Conditions: Leukemia; Lymphoma; HIV
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI); Drug: Fludarabine; Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012 - Condition: Neurofibromatosis Type 1
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Condition: Bone Metastases
Intervention: Radiation: STAT RT planning and delivery workflow
Sponsors: University of Virginia; University of Virginia
Recruiting - verified July 2011 - Condition: Myelodysplastic Syndromes
Intervention:
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified August 2011 - Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
Intervention: Drug: BMN 673
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified March 2012 - Conditions: Hepato/Renal Fibrocystic Disease; Autosomal Recessive Polycystic Kidney Disease; Joubert Syndrome; Bardet Biedl Syndrome; Meckel-Gruber Syndrome; Congenital Hepatic Fibrosis; Caroli Syndrome; Oro-Facial-Digital Syndrome Type I; Nephronophithisis; Glomerulocystic Kidney Disease
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib, Imatinib
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital; Novartis
Recruiting - verified September 2009 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Arsenic trioxide
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; National Institutes of Health (NIH); Cephalon
Recruiting - verified March 2012 - Condition: Malignant Lymphoma, Stem Cell Type
Interventions: Drug: Plerixafor (Mozobil); Drug: Plerixafor + G-CSF
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada; Genzyme
Not yet recruiting - verified July 2011 - Conditions: Hematologic Malignancies; Acute Leukemia; Myelodysplastic Syndrome (MDS); Specific Subtypes of Refractory Anemia (RA) or Refractory Anemia With Ringed Sideroblasts(RARS) Subtypes; Myeloproliferative Disorder (MPD); Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Myeloma; Aplastic Anemia
Interventions: Drug: Fludarabine; Drug: Thiotepa; Radiation: Total Body Irradiation (TBI); Biological: Donor Lymphocyte Infusion (DLI); Drug: Cyclophosphamide (CY); Drug: Tacrolimus; Drug: Mycophenolate mofetil; Device: Hematopoietic stem cell transplantation
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified January 2012 - Conditions: Maxillary Cyst; Bone Loss of Substance
Intervention: Other: Autologous Mesenchymal Stem Cells
Sponsors: Red de Terapia Celular; Red de Terapia Celular; Sanidad de Castilla y Leon (SACYL); Instituto de Biologia y Genetica Molecular (IBGM), University of Valladolid; Scientific Park Foundation, University of Valladolid; Centro en Red de Medicina Regenerativa de Castilla y Leon
Recruiting - verified April 2012 - Condition: Leukemia
Intervention: Drug: PEG-IFNá-2a
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: decitabine injection
Sponsors: Janssen Korea, Ltd., Korea; Janssen Korea, Ltd., Korea
Recruiting - verified April 2012 - Conditions: Cancer; Metastatic Malignant Neoplasm to Femur; Risk of Fracture
Interventions: Procedure: Surgery Alone; Other: Combined Surgery and Radiation therapy
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified May 2012 - Conditions: Leukemia; Chronic Myelogenous Leukemia
Interventions: Drug: Fludarabine; Drug: Busulfan; Procedure: NK cell infusion:; Drug: Interleukin-2; Drug: Anti-Thymocyte Globulin; Procedure: Allogeneic related Stem Cell Transplant; Drug: Tacrolimus; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Neural Tube Defects; Anemia; Leukemia, Myeloid; Bone Marrow Transplant Failure; Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders
Interventions: Drug: CIK cells; Drug: Cyclosporine; Drug: Mycophenolate Mofetil; Drug: Thymoglobulin
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011 - Condition: Sarcoma
Interventions: Drug: Docetaxel (Taxotere); Drug: Irinotecan
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified January 2012 - Conditions: Polycythemia Vera; Essential Thrombocythemia; Primary Myelofibrosis
Interventions: Drug: PegIntron; Drug: Pegasys; Drug: PegIntron; Drug: Pegasys; Drug: Hydrea; Drug: Multiferon
Sponsors: Odense University Hospital; Thomas Stauffer Larsen
Recruiting - verified June 2011 - Conditions: Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia
Interventions: Procedure: allogeneic stem cell transplantation; Procedure: 5-azacytidine until progress
Sponsors: Universitätsklinikum Hamburg-Eppendorf; Universitätsklinikum Hamburg-Eppendorf
Recruiting - verified July 2011 - Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
Interventions: Drug: Preparative Regimen; Biological: Intravenous Recombinant Human IL-15 (rhIL-15)
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012 - Conditions: Acute Myelocytic Leukemia; Myelodysplastic Syndrome
Intervention: Drug: Azacitidine
Sponsors: Dresden University of Technology; Dresden University of Technology; University Hospital Dresden
Recruiting - verified February 2012 - Condition: Myelodysplastic Syndromes
Interventions: Drug: Group 2: Placebo; Drug: Group 1: Epoetin alfa
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified March 2012 - Condition: Prevention of GvHD in Patients With Hematological Malignancies Undergoing AHSCT
Intervention: Drug: RGI-2001
Sponsors: Regimmune Inc.; Regimmune Inc.; Pacific-Link Regulatory Consulting LLC
Recruiting - verified January 2012 - Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Other: laboratory biomarker analysis; Other: flow cytometry; Drug: systemic chemotherapy; Biological: therapeutic allogeneic lymphocytes
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012 - Conditions: Adult Spinal Cord Neoplasm; Spinal Bone Metastases; Spinal Cord Metastases
Intervention: Procedure: therapeutic conventional surgery
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified November 2011 - Conditions: Acromegaly; Pituitary Tumor
Intervention:
Sponsors: Huashan Hospital; Huashan Hospital; National Natural Science Foundation of China
Recruiting - verified June 2011 - Condition: Low and Intermediate 1 Risk MDS
Intervention: Drug: Lenalidomide and azacitidine combination
Sponsors: Rush University Medical Center; Rush University Medical Center; Celgene Corporation
Recruiting - verified June 2011 - Conditions: Bone Cancer; Chondrosarcoma; Ewing's Sarcoma; Osteosarcoma; Rhabdomyosarcoma
Interventions: Drug: Feraheme; Procedure: MR Scan
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011 - Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Intervention: Drug: Decitabine plus Fludarabine and Busulfan
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified October 2011 - Condition: Bone Metastases
Intervention: Radiation: BS, SPECT/CT, PET/CT, MRI
Sponsors: Turku University Hospital; Turku University Hospital
Recruiting - verified November 2011 - Conditions: Myeloid Malignancies; Acute Myelogenous Leukemia; Chronic Myelogenous Leukemia; Myeloproliferative Disorders; Myelodysplastic Syndrome
Interventions: Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose); Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (TBI)
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified June 2011 - Conditions: Coronary Artery Disease; Proteus Syndrome; Coffin - Sins Syndrome; Familial Isolated Hyperparathyroidism; Dubouitz Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2012 - Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Interventions: Drug: Preparative Regimen; Biological: NK Cell Product; Drug: Interleukin-2; Biological: Donor CD34+ Cells; Biological: Anti-thymocyte globulin
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified June 2011 - Condition: Cushing Syndrome
Intervention: Procedure: surgery
Sponsors: Samsung Medical Center; Samsung Medical Center; Asan Medical Center; Severance Hospital; Konkuk University Medical Center
Recruiting - verified June 2011 - Conditions: Neurofibromatosis 1; Neurofibromatosis Type 1; NF 1; Neurofibroma, Plexiform
Intervention: Drug: AZD6244 hyd sulfate
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Ewing's Sarcoma; Osteosarcoma; Astrocytoma; Atypical Teratoid/Rhabdoid Tumor; Ependymoma; Germ Cell Tumor; Glioma; Medulloblastoma; Rhabdoid Tumor; Retinoblastoma; Clear Cell Sarcoma; Renal Cell Carcinoma; Wilms Tumor; Hepatoblastoma; Neuroblastoma; Rhabdomyosarcoma
Intervention: Drug: sirolimus
Sponsors: Emory University; Emory University; Children's Healthcare of Atlanta
Recruiting - verified October 2011 - Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified November 2011 - Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012 - Condition: MDS
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Basal Cell Carcinoma; Gorlin Syndrome; Nevoid Basal Cell Carcinoma Syndrome
Interventions: Drug: LDE225; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Revlimid
Sponsors: Arbeitsgemeinschaft medikamentoese Tumortherapie; Arbeitsgemeinschaft medikamentoese Tumortherapie; Celgene Corporation
Recruiting - verified June 2011 - Condition: Hematological Malignancies
Interventions: Radiation: Total Body Irradiation; Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate mofetil; Drug: Fludarabine; Drug: Thiotepa; Genetic: Hematopoietic stem cell transplantation
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified January 2012 - Conditions: DDD; Deformity; Tumor; Fracture
Intervention:
Sponsors: Biomet, Inc.; Biomet, Inc.
Recruiting - verified February 2012 - Conditions: Multiple Myeloma; Non-Hodgkin Lymphoma; Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Chronic Myeloid Leukemia
Intervention: Drug: OPB-51602
Sponsors: Otsuka Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.
Recruiting - verified April 2012 - Conditions: Hodgkin's Lymphoma; Leukemia; Myelodysplastic Syndrome(MDS); Multiple Myeloma; Non Hodgkin's Lymphoma
Intervention: Procedure: Bone Marrow Transplant
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: 5-Azacitidine
Sponsors: University of Utah; University of Utah; Celgene Corporation
Recruiting - verified January 2012 - Conditions: Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome RAEB 1
Interventions: Drug: Lupron; Drug: 18F FLT; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Tacrolimus; Drug: Total Body Irradiation
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Osteoporosis; Hypercalcemia of Malignancy; Hyperparathyroidism; Bone Diseases, Endocrine
Interventions: Drug: Parathyroid Hormone-related Protein (1-36); Drug: parathyroid hormone (1-34); Drug: PTH (1-34) and PTHrP (1-36)
Sponsors: University of Pittsburgh; University of Pittsburgh
Not yet recruiting - verified January 2012 - Condition: Hematologic Neoplasms
Intervention: Procedure: Intrabone injection
Sponsors: Università degli Studi di Brescia; Università degli Studi di Brescia
Recruiting - verified December 2011 - Condition: Bone Metastasis
Intervention: Device: Philips MR-guided HIFU system
Sponsors: Philips Healthcare; Philips Healthcare
Recruiting - verified December 2011 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: cyclosporine; Drug: pravastatin sodium; Drug: mitoxantrone hydrochloride; Drug: etoposide; Procedure: bone marrow aspiration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Adult Spinal Cord Neoplasm; Childhood Spinal Cord Neoplasm; Recurrent Adult Spinal Cord Neoplasm; Recurrent Childhood Spinal Cord Neoplasm; Spinal Bone Metastases; Spinal Cord Metastases
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic conventional surgery; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Leukemia, Myelocytic, Acute
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Busulfan and Cyclophosphamide (Bu/Cy); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI)
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012 - Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic DiseasesConditions: Chronic Leukemia; Acute Leukemia; Hodgkin's Disease; Non-Hodgkin's Lymphoma; Myelodysplastic Syndrome
Intervention: Procedure: Peripheral Blood Stem Cell Transplant
Sponsors: Northside Hospital, Inc.; Northside Hospital, Inc.; Blood and Marrow Transplant Group of Georgia
Recruiting - verified September 2011 - Condition: MDS
Interventions: Drug: Azacitidine; Drug: Azacitidine associated with Valproic acid; Drug: Azacitidine associated with Lenalidomide
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified November 2011 - Condition: Conventional Chondrosarcoma
Interventions: Drug: IPI-926; Drug: Placebo Arm
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Severe Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Myeloproliferative Syndromes; Chronic Myelogenous Leukemia; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Large Granulocytic Leukemia
Intervention: Procedure: Allogeneic transplantation
Sponsors: Scripps Health; Scripps Health
Recruiting - verified June 2011 - Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Filgrastim, Ifosfamide, Etoposide, Dexamethasone, Mesna
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Brain Tumor; Spinal Tumor; Glial Tumour of Brain; Ependymal Tumour of Brain; Spinal Cord Ependymoma; Anaplastic Ependymoma
Interventions: Drug: Bevacizumab; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified February 2012 - Conditions: Hematologic Malignancies; Nonmalignant Diseases; Immunodeficiencies; Hemoglobinopathies; Genetic Inborn Errors of Metabolism; Fanconi's Anemia,; Thalassemia; Sickle Cell Disease
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Thrasher Research Fund
Recruiting - verified September 2011 - Condition: Cancer
Interventions: Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: fertility assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Institut Catala D'Oncologia
Recruiting - verified February 2011 - Conditions: Myelodysplastic Syndrome,; Transfusional Iron Overload
Intervention: Drug: Deferasirox
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Leukemia; Lymphoma; Myelodysplastic Syndrome
Intervention: Drug: Bortezomib, Tacrolimus, Methotrexate
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified May 2011 - Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib stop
Sponsors: University Hospital, Bordeaux; University Hospital, Bordeaux
Recruiting - verified December 2011 - Conditions: Ewing's Sarcoma/Soft Tissue Sarcoma; Neuroblastoma; Brain Tumors
Interventions: Drug: plerixafor; Drug: plerixafor; Drug: plerixafor
Sponsors: Genzyme; Genzyme
Recruiting - verified January 2012 - Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vitamin D Deficiency
Interventions: Dietary Supplement: Vitamin D and Calcium Citrate; Dietary Supplement: Placebo
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles; The Leukemia and Lymphoma Society
Recruiting - verified September 2011 - Condition: GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Conditions: Acute Myeloid Leukemia; High Grade Myelodysplastic Syndrome
Intervention:
Sponsors: University of Rochester; University of Rochester; Ohio State University; Rochester General Hospital
Recruiting - verified November 2011 - Conditions: Craniopharyngioma; Obesity
Interventions: Radiation: Radiation; Other: wait and watch
Sponsors: Klinikum Oldenburg gGmbH; Klinikum Oldenburg gGmbH; German society of pediatric oncology and hematology (GPOH); Association of pediatric endocrinology (APE); German Society for Endocrinology (DGE); Working group pediatric radiation oncology (APRO); Task force of the German society of radiation oncology (DEGRO); Deutsche Kinderkrebsstiftung (DKKS)
Recruiting - verified July 2011 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
Sponsors: American University of Beirut Medical Center; American University of Beirut Medical Center
Recruiting - verified January 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Secondary Acute Myeloid Leukemia
Interventions: Radiation: Indium-111 111In anti-CD45 monoclonal antibody BC8 (dosimetric dose); yttrium Y 90 anti-CD45 monoclonal antibody BC8 (therapeutic dose); Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Other: flow cytometry; Genetic: cytogenetic analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Myelodysplastic Syndrome
Intervention: Drug: Azacitidine
Sponsors: Groupe Francophone des Myelodysplasies; Groupe Francophone des Myelodysplasies
Recruiting - verified February 2011 - Conditions: Double Cord Blood Transplant; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Myelofibrosis; Acute Lymphoblastic Leukemia; Chronic Myelocytic Leukemia; Non Hodgkins Lymphoma; Hodgkins Lymphoma; Chronic Lymphocytic Leukemia
Intervention: Drug: TXA127
Sponsors: US Biotest, Inc.; US Biotest, Inc.; Tarix Pharmaceuticals
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Drug: bortezomib; Other: randomization to study procedures only
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified April 2012 - Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplasia
Intervention: Biological: human myeloid progenitor cells
Sponsors: Cellerant Therapeutics; Cellerant Therapeutics; Department of Health and Human Services
Recruiting - verified March 2012 - Conditions: GVHD; Adult Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Myelodysplastic Syndrome
Interventions: Biological: Anti-human-T-lymphocyte Immune Globulin, Rabbit; Biological: Placebo
Sponsors: Fresenius Biotech GmbH; Fresenius Biotech GmbH; Fresenius Biotech North America
Recruiting - verified April 2012 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.
Sponsors: Hospices Civils de Lyon; Hospices Civils de Lyon
Recruiting - verified February 2011 - Conditions: Fungal Infection; Leukemia; Myelodysplastic Syndromes
Intervention: Drug: caspofungin acetate
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: Clofarabine; Drug: Idarubicin; Drug: Cytarabine; Drug: Fludarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate CancerConditions: Breast Cancer; Prostate Cancer; Osteopenia; Osteoporosis
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified February 2012 - Condition: Transplant-Related Cancer
Interventions: Biological: Hepatitis A; Biological: PCV 13
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Myelodysplastic Syndrome (MDS); Thrombocytopenia
Intervention: Drug: Eltrombopag
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline
Recruiting - verified January 2012 - Conditions: Cancer; Bone Metastases
Interventions: Device: F-18 PET bone scan; Device: Tc-99m bone scan
Sponsors: Seattle Nuclear Medicine; Seattle Nuclear Medicine
Recruiting - verified July 2011 - Condition: Non Hematologic, Malignant Solid Tumour, Excluding Primary Brain or Spinal Tumours
Intervention: Drug: PG545
Sponsors: Progen Pharmaceuticals; Progen Pharmaceuticals; Statistical Revelations Pty Ltd; Datapharm Australia Pty Ltd
Recruiting - verified June 2011 - Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia
Intervention: Drug: Decitabine
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital; Janssen, LP
Recruiting - verified January 2011 - Condition: Bone Metastases
Interventions: Drug: Dexamethasone; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified March 2012 - Condition: Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Myelodysplastic Syndrome; Myelofibrosis; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia
Interventions: Drug: Luitpold Azacitidine; Drug: Vidaza®
Sponsors: Luitpold Pharmaceuticals; Luitpold Pharmaceuticals
Recruiting - verified June 2011 - Condition: Leukemia
Interventions: Drug: Omacetaxine; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; ChemGenex Pharmaceuticals
Recruiting - verified December 2011 - Conditions: Neuroblastoma; Ewings Sarcoma; Osteogenic Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma
Intervention: Biological: Autologous dendritic cell vaccine with adjuvant
Sponsors: Penn State University; Penn State University; Solving Kids’ Cancer
Recruiting - verified January 2012 - Condition: Non Melanoma Skin Cancer of the Nose
Intervention: Biological: engineered nasal cartilage graft
Sponsors: University Hospital, Basel, Switzerland; University Hospital, Basel, Switzerland
Recruiting - verified May 2012 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Tasigna
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Curcumin; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Not yet recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Brain Tumor; Head and Neck Tumor; Skull Base Tumor
Intervention: Procedure: PET scan
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: sirolimus; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Refractory or Relapsed Osteosarcoma
Intervention: Drug: Everolimus
Sponsors: Hospital Santa Marcelina; Hospital Santa Marcelina
Recruiting - verified September 2011 - Condition: Leukemia
Interventions: Drug: Azacitidine; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Onyx Therapeutics, Inc.; Celgene Corporation
Recruiting - verified May 2012 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Chronic Myeloid Leukemia
Intervention:
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified December 2010 - Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Decitabine
Sponsors: Associazione Italiana per lo Studio delle Sindromi Mielodisplastiche; Associazione Italiana per lo Studio delle Sindromi Mielodisplastiche; Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Recruiting - verified June 2011 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: clofarabine; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Genetic: fluorescence in situ hybridization; Procedure: peripheral blood stem cell transplantation; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: MDS; CMML; AML
Intervention: Drug: SGI-110
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified November 2011 - Conditions: Ewing's Sarcoma; Primitive Neuroectodermal Tumor (PNET); Askin's Tumor of the Chest Wall; Extraosseous Ewing's Sarcoma (EOE)
Intervention: Drug: Zalypsis
Sponsors: PharmaMar; PharmaMar
Recruiting - verified August 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Intervention: Other: computer-assisted intervention
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Chronic Myelogenous Leukemia (CML)
Intervention: Other: compliance supporting measures
Sponsors: Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH; Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH; Crolll Gmbh
Recruiting - verified February 2012 - Condition: Chronic Myeloid Leukemia
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; ICON Clinical Research
Recruiting - verified May 2012 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide; Other: Placebo
Sponsors: Fundación General de la Universidad de Salamanca; Fundación General de la Universidad de Salamanca; Celgene Corporation
Recruiting - verified July 2011 - Condition: Myelodysplastic Syndromes
Interventions: Drug: Lenalidomide 50 mg/day Days 1-28; Drug: Lenalidomide 10 mg/day
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Graft Versus Host Disease; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: palifermin; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Transfusional Iron Overload; Thalassemia Major; Sickle Cell Disease; Myelodysplastic Syndromes; Aplastic Anemia
Intervention: Device: Hepatic biomagnetic susceptibility measurement
Sponsors: Columbia University; Columbia University; Food and Drug Administration (FDA)
Recruiting - verified September 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Anemia With Excess Blasts; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenström Macroglobulinemia
Interventions: Procedure: peripheral blood stem cell transplantation; Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: sirolimus; Drug: mycophenolate mofetil; Other: flow cytometry; Genetic: fluorescence in situ hybridization; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Other: Early hospital discharge; Other: Medical chart review; Other: Questionnaire administration; Other: Electronic billing information review
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center
Recruiting - verified February 2012 - Conditions: Melanoma; Ovarian Cancer; Sarcoma; BONE; CNS-SPINAL CD/MEMBR,NOS; LYMPH NODES; SOFT TISSUE
Interventions: Radiation: IGIMRT using a single dose of 24 Gy; Radiation: IGIMRT 27 Gy in 3 fractions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Pisa
Recruiting - verified March 2012 - Condition: Osteosarcoma
Intervention: Drug: Mifamurtide
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Conditions: Myelodysplastic Syndromes; MDS; RAEB; Chronic Myelomonocytic Leukemia
Intervention: Drug: ON 01910.Na
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; The Leukemia and Lymphoma Society
Recruiting - verified April 2012 - Condition: Chordoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Acute Lymphoblastic Leukemia (ALL); Acute Myelogenous Leukemia (AML); Myelodysplastic Syndrome (MDS); Non-Hodgkin's Lymphoma; Hodgkin's Disease
Intervention: Drug: NiCord®
Sponsors: Gamida Cell ltd; Gamida Cell ltd
Recruiting - verified May 2012 - Condition: Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: hydroxychloroquine; Drug: imatinib mesylate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: University of Glasgow; Lynn McMahon; Medical Research Council; CRUK Trials unit Glasgow
Recruiting - verified November 2011 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Tasigna
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Cancer; Allogeneic Peripheral Blood Stem Cell Transplant; Bone Marrow Transplantation
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified July 2011 - Condition: Acute Myeloid Leukemia (AML)
Intervention: Drug: Panobinostat
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)
Intervention: Drug: Imatinib Mesylate
Sponsors: Hospital Santa Marcelina; Hospital Santa Marcelina
Recruiting - verified July 2011 - Condition: Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: trabectedin; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; Sarcoma Alliance for Research through Collaboration
Recruiting - verified November 2011 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib, interferon-alfa
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Non-Small-Cell Lung Carcinoma; Liver Cancer; Adrenal Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified October 2011 - Conditions: Acute Myeloid Leukemia (AML); Acute Lymphocytic Leukemia (ALL); Chronic Myelogenous Leukemia (CML); Myelodysplastic Syndrome (MDS); Myeloproliferative Neoplasms (MPN)
Intervention: Drug: KB004, Monoclonal Antibody
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified October 2011 - Condition: Chronic Myeloid Leukemia
Intervention: Procedure: Stem Cell and Mutational Assay
Sponsors: University of British Columbia; University of British Columbia; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Myeloid Leukemia, Chronic, Chronic Phase
Interventions: Drug: Imatinib; Drug: Dasatinib
Sponsors: Newcastle University; Newcastle University; Newcastle-upon-Tyne Hospitals NHS Trust; Bristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Hammersmith Hospitals NHS Trust
Recruiting - verified October 2011 - Conditions: Hematopoietic/Lymphoid Cancer; Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Atypical Chronic Myeloid Leukemia, BCR-ABL Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Cytomegalovirus Infection; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: infection prophylaxis and management; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: DNA analysis; Genetic: RNA analysis; Procedure: management of therapy complications; Drug: ganciclovir; Drug: valganciclovir; Drug: foscarnet sodium; Procedure: antiviral therapy; Genetic: polymerase chain reaction; Genetic: protein expression analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Lymphomas; Bone Marrow Failure; Hemoglobinopathy; Immune Deficiency; Osteopetrosis; Cytopenias; White Blood Cell Abnormalities; Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
Sponsors: University of California, San Francisco; University of California, San Francisco
Available - verified June 2011 - Conditions: AML; ALL; CML in Blast Crisis; High-Risk MDS; Multiple Myeloma
Intervention: Drug: TG02 citrate
Sponsors: Tragara Pharmaceuticals, Inc.; Tragara Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: West Virginia University; William Tse, MD
Recruiting - verified September 2011 - Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia
Intervention: Biological: 90Y-AHN-12
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: CML; Nilotinib; Imatinib Resistant; Imatinib Intolerant
Intervention: Drug: nilotinib
Sponsors: Novartis Korea Ltd.; Novartis Korea Ltd.
Recruiting - verified June 2011 - Condition: High-Risk Myelodysplastic Syndromes
Intervention: Drug: Azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Conditions: Myelodysplastic Syndromes; Secondary Acute Myeloid Leukemia
Interventions: Other: Reduced Intensity Conditioning; Other: Myeloablative conditioning
Sponsors: European Group for Blood and Marrow Transplantation; European Group for Blood and Marrow Transplantation; Pierre Fabre Medicament
Recruiting - verified December 2011 - Condition: Leukemia
Interventions: Drug: 5-azacytidine; Drug: PKC412
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Conditions: Neuroblastoma; Rhabdomyosarcoma; Lymphoma; Wilm's Tumor; Ewing's Sarcoma
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics; Solving Kids’ Cancer
Recruiting - verified March 2012 - Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
Interventions: Drug: micafungin; Drug: posaconazole
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Astellas Pharma US, Inc.
Recruiting - verified January 2012 - Conditions: Lymphoma; Myeloma
Interventions: Drug: Pomalidomide; Drug: Pomalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified February 2012 - Condition: Leukemia
Intervention: Drug: Alemtuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Conditions: Leukemia; Myelodysplastic Syndrome; Leukemia, Myeloid, Acute
Interventions: Drug: anidulafungin 200 mg q48h; Drug: anidulafungin 300 mg q72h
Sponsors: Radboud University; Radboud University
Recruiting - verified January 2012 - Condition: Bone Metastases of a Malignant Tumor
Interventions: Drug: Aminobiphosphonate; Drug: Simvastatin
Sponsors: VU University Medical Center; VU University Medical Center
Recruiting - verified February 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Neuroblastoma
Intervention: Drug: 3F8 and 13-cis-retinoic acid
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Procedure: umbilical cord blood transplantation; Drug: fludarabine phosphate; Drug: cyclophosphamide; Procedure: ex vivo-expanded cord blood progenitor cell infusion; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Conditions: Severe Aplastic Anemia; MDS (Myelodysplastic Syndrome)
Interventions: Device: Miltenyi CD34 Reagent System; Other: Donor derived G-CSF mobilized PBC
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: MDS; AML; CMMOL
Intervention:
Sponsors: iOMEDICO AG; iOMEDICO AG
Recruiting - verified May 2012 - Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following; Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
Interventions: Drug: midostaurin, bortezomib,; Drug: mitoxantrone hydrochloride, etoposide, cytarabine, midostaurin, bortezomib
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Novartis; Millennium Pharmaceuticals, Inc.
Recruiting - verified November 2011 - Condition: Chronic Myeloid Leukemia
Interventions: Drug: Placebo; Drug: Armodafinil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Stem Cell Leukemia of Unclear Lineage; Graft Versus Host Disease
Intervention: Drug: extracorporeal photopheresis
Sponsors: University of Kansas; University of Kansas; Therakos
Recruiting - verified October 2011 - Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelomonocytic Leukemia
Intervention: Drug: Clofarabine
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Genzyme
Recruiting - verified November 2011 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: ruxolitinib phosphate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Darbepoetin alpha; Drug: Filgrastim; Procedure: Blood Red Cell Transfusion
Sponsors: Barts & The London NHS Trust; Barts & The London NHS Trust; Cancer Research UK; Amgen
Not yet recruiting - verified July 2010 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: azacitidine; Drug: busulfan; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Other: enzyme-linked immunosorbent assay; Genetic: microarray analysis; Other: questionnaire administration; Other: preventative dietary intervention
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: docetaxel; Genetic: RNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: circulating tumor cell analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); All Ireland Cooperative Oncology Research Group
Recruiting - verified January 2011 - Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma
Intervention: Drug: Sargramostim and plerixafor
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified November 2011 - Conditions: Osteosarcoma; Ewing's Sarcoma Family of Tumors; Rhabdomyosarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcomas
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified November 2011 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Azacitidine for Injection; Drug: Vidaza®
Sponsors: Bioniche Pharma USA LLC; Bioniche Pharma USA LLC
Recruiting - verified April 2012 - Conditions: Chronic Myeloproliferative Disorders; Cognitive/Functional Effects; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonmalignant Neoplasm
Interventions: Other: biologic sample preservation procedure; Other: cytology specimen collection procedure
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); de Novo Myelodysplastic Syndromes; Myelodysplastic Syndrome With Isolated Del(5q); Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: bendamustine hydrochloride; Drug: idarubicin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Leukemia
Intervention:
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified February 2012 - Conditions: Bone Metastases; Castration-Resistant Prostate Cancer
Interventions: Drug: Alpharadin® (Radium-223 chloride) + docetaxel; Drug: Docetaxel
Sponsors: Algeta ASA; Algeta ASA; Bayer
Recruiting - verified October 2011 - Conditions: Hematologic Malignancy; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia in Blast Crisis; Anemia, Refractory, With Excess of Blasts; Chronic Myeloproliferative Disease; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Marginal Zone B-cell Lymphoma; Follicular Lymphoma; Lymphoplasmacytic Lymphoma; Mantle-Cell Lymphoma; Prolymphocytic Lymphoma; Large Cell Non-Hodgkin's Lymphoma; Lymphoblastic Lymphoma; Burkitt's Lymphoma; High Grade Non-Hodgkin's Lymphoma
Interventions: Biological: Treg cells; Biological: CD3+ Teff cells; Drug: Fludarabine; Drug: Cyclophosphamide; Radiation: Total body irradiation; Biological: Umbilical cord blood transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified December 2011 - Condition: Follicular Lymphoma
Intervention: Other: Combination of treatment modalities
Sponsors: St. Louis University; St. Louis University
Recruiting - verified May 2010 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Zileuton
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified February 2012 - Condition: Acromegaly
Interventions: Drug: Pasireotide (SOM230); Drug: octreotide LAR 30mg or lanreotide ATG 120mg
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Conditions: Myelodysplastic Syndrome; MDS
Interventions: Drug: Prednisone; Drug: Lenalidomide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention: Drug: ZD4054
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; AstraZeneca
Recruiting - verified November 2011 - Conditions: Bone Cancer; Bone Metastases; Pain
Interventions: Device: Exablate treatment; Radiation: Radiation
Sponsors: InSightec; InSightec
Recruiting - verified February 2012 - Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaConditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: bortezomib; Drug: mitoxantrone hydrochloride; Drug: etoposide; Drug: cytarabine; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified April 2012 - Conditions: Acoustic Schwannoma; Adult Anaplastic Meningioma; Adult Ependymoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Meningeal Hemangiopericytoma; Adult Papillary Meningioma; Neurofibromatosis Type 1; Neurofibromatosis Type 2; Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012 - Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Biological: anti-thymocyte globulin; Biological: rituximab; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: management of therapy complications; Procedure: peripheral blood stem cell transplantation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Multiple Myeloma
Interventions: Device: CliniMACS Fractionation system; Device: CliniMACS Fractionation system; Device: CliniMACS Fractionation system
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011 - Conditions: Bone Cancer; Bone Metastases; Pain
Intervention: Device: ExAblate 2100
Sponsors: InSightec; InSightec
Recruiting - verified February 2012 - Conditions: Breast Cancer; Lymphoma
Intervention: Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011 - Conditions: Osteoporosis; Multiple Myeloma; Vertebral Fracture
Intervention:
Sponsors: German Cancer Research Center; German Cancer Research Center; University of Heidelberg
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention:
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified June 2011 - Condition: Myelodysplastic Syndrome
Intervention: Drug: Temsirolimus
Sponsors: Dresden University of Technology; Dresden University of Technology; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified July 2011 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: Nelfinavir
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Untreated Adult Acute Myeloid Leukemia; Myeloproliferative Neoplasm With 10% Blasts or Higher
Interventions: Biological: filgrastim; Drug: clofarabine; Drug: cytarabine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; B-cell Chronic Lymphocytic Leukemia; Myelodysplasia
Interventions: Drug: ABT-348; Drug: ABT-348; Drug: ABT-348 and azacitidine
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Conditions: Prostate Cancer; Erectile Dysfunction
Intervention: Biological: injection of bone marrow mononucleated cells
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified April 2011 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Erythroleukemia (M6a); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Pure Erythroid Leukemia (M6b); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Erythroleukemia (M6); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: double-unit umbilical cord blood transplantation; Other: cytogenetic analysis; Procedure: bone marrow aspiration; Other: fluorescence in situ hybridization; Drug: busulfan; Drug: cyclophosphamide; Drug: anti-thymocyte globulin; Drug: methylprednisolone; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: Myelodysplastic Syndrome
Intervention: Other: Maitake
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; YUKIGUNI COMPANY; Weill Medical College of Cornell University
Recruiting - verified October 2011 - Conditions: Hematopoietic/Lymphoid Cancer; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: midostaurin; Drug: azacitidine; Other: laboratory biomarker analysis; Other: bone marrow aspiration; Other: liquid chromatography; Other: flow cytometry; Other: mutation analysis; Other: pharmacological study; Other: mass spectrometry; Other: protein expression analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified March 2012 - Condition: Myelodysplasia
Intervention:
Sponsors: Saint-Louis Hospital, Paris, France; Saint-Louis Hospital, Paris, France; Hospital Avicenne; University Hospital, Grenoble; University Hospital, Clermont-Ferrand
Recruiting - verified December 2011 - Condition: Bone Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: Azacitidine combined to Lenalidomide
Sponsors: Groupe Francophone des Myelodysplasies; Groupe Francophone des Myelodysplasies; Celgene Corporation
Recruiting - verified March 2012 - Conditions: Leukemia, Myelogenous, Acute; Myelodysplastic Syndromes
Intervention: Drug: OXi4503
Sponsors: University of Florida; University of Florida; The Leukemia and Lymphoma Society
Recruiting - verified March 2012 - Conditions: Cancer Survivor; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Testicular Germ Cell Tumor
Interventions: Genetic: DNA analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Vanderbilt University; Vanderbilt University; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Myelodysplastic Syndrome
Intervention: Drug: Erlotinib
Sponsors: Groupe Francophone des Myelodysplasies; Groupe Francophone des Myelodysplasies; Roche Pharma AG
Recruiting - verified March 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Pediatric Solid Tumors
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified February 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: Lenalidomide
Sponsors: Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH; Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH; ClinAssess - Gesellschaft für klinische Forschung mbH
Recruiting - verified July 2010 - Conditions: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: bortezomib; Drug: belinostat; Other: laboratory biomarker analysis; Genetic: western blotting; Other: pharmacological study; Other: flow cytometry
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Intervention: Drug: Plerixafor
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genzyme
Recruiting - verified November 2011 - Condition: Neurofibromatosis Type 1
Interventions: Other: Plyometric training program; Other: Control Group
Sponsors: Shriners Hospitals for Children; Shriners Hospitals for Children; Thrasher Research Fund; University of Utah
Recruiting - verified September 2011 - Conditions: Post-transplant Lymphoproliferative Disease; Solid Organ Transplant; Stem Cell Transplant (Bone Marrow Transplant); Epstein Barr Virus Infections
Interventions: Drug: bortezomib; Drug: rituximab
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Myelodysplastic Syndromes
Interventions: Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Leukemia, Myeloid
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Myelodysplastic Syndrome
Intervention: Drug: Clofarabine
Sponsors: Groupe Francophone des Myelodysplasies; Groupe Francophone des Myelodysplasies; Genzyme
Recruiting - verified March 2012 - Conditions: Brain Cancer; Cancer
Intervention: Procedure: Bone marrow specimen banking
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012 - Condition: Myelodysplastic Syndrome
Intervention: Drug: 5-Azacytidine and Lenalidomide
Sponsors: Tel-Aviv Sourasky Medical Center; Tel-Aviv Sourasky Medical Center
Recruiting - verified March 2012 - Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute; Leukemia, Myelocytic, Chronic; Myeloproliferative Disorders; Myelodysplastic Syndromes; Multiple Myeloma; Leukemia, Lymphocytic, Chronic; Hodgkin's Disease; Lymphoma, Non-Hodgkin
Interventions: Biological: Mesenchymal stem cells; Other: Isotonic solution
Sponsors: University Hospital of Liege; University Hospital of Liege; AZ Sint-Jan AV; Ziekenhuis Netwerk Antwerpen (ZNA); Jules Bordet Institute; Universiteit Antwerpen; Katholieke Universiteit Leuven; AZ-VUB; Cliniques universitaires Saint-Luc- Université Catholique de Louvain; University Hospital, Ghent; University Hospital of Mont-Godinne; Queen Fabiola Children's University Hospital
Recruiting - verified September 2011 - Conditions: Acute Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Biphenotypic Leukemia; Pre-leukemic Syndromes; Monosomy 7; Bone Marrow Clonal Malformations; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia
Intervention: Other: Withdrawal of immunosuppression and donor lymphocyte infusion
Sponsors: University of California, San Francisco; University of California, San Francisco; All Children's Hospital
Recruiting - verified March 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Intervention: Biological: gene-modified T cells targeted to B-ALL tumor cells
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Conditions: Adult Acute Myeloid Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: 5-fluoro-2-deoxycytidine; Drug: tetrahydrouridine; Other: laboratory biomarker analysis; Genetic: reverse transcriptase-polymerase chain reaction; Genetic: DNA methylation analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011 - Condition: Osteosarcoma
Interventions: Drug: Chemotherapy; Drug: Endostar
Sponsors: Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd; Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Recruiting - verified July 2011 - Condition: Leukemia
Interventions: Drug: 5-Azacytidine; Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified April 2012 - Condition: Myelodysplastic Syndrome (MDS)
Interventions: Drug: oral LBH589/panobinostat; Drug: oral LBH589/panobinostat + Epoitin Alfa HEXAL®
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Conditions: Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: tacrolimus; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: laboratory biomarker analysis; Procedure: flow cytometry; Radiation: total-body irradiation; Genetic: fluorescence in situ hybridization; Genetic: western blotting; Procedure: polymerase chain reaction; Biological: filgrastim
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Acute Promyelocytic Leukemia (M3); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine; Drug: filgrastim; Procedure: ex-vivo umbilical cord blood expansion; Other: DNA analysis; Procedure: bone marrow aspiration; Genetic: cytogenetic analysis; Other: flow cytometry; Other: fluorescence in situ hybridization; Other: laboratory biomarker analysis; Drug: clofarabine; Procedure: ex vivo-expanded cord blood progenitor cell infusion
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Anemia
Interventions: Drug: Lenalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Conditions: Bone Mineral Density; Bone Strength
Interventions: Device: LMHF mechanical stimulation active device; Device: LMHF mechanical stimulation placebo device
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified November 2011 - Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute; Leukemia, Myeloid, Chronic
Intervention: Drug: Stem cell Transplantation
Sponsors: Tehran University of Medical Sciences; Tehran University of Medical Sciences
Recruiting - verified July 2011 - Condition: Bone Metastases
Intervention: Device: ExAblate 2100
Sponsors: InSightec; InSightec
Recruiting - verified October 2011 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; B-cell Chronic Lymphocytic Leukemia; Burkitt Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: carmustine; Drug: etoposide; Drug: cytarabine; Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: tacrolimus; Drug: mycophenolate mofetil; Radiation: total-body irradiation; Drug: melphalan; Procedure: autologous-allogeneic tandem hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: allogeneic bone marrow transplantation; Genetic: fluorescence in situ hybridization; Other: flow cytometry; Genetic: RNA analysis; Other: laboratory biomarker analysis; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Procedure: allogeneic peripheral blood mononuclear stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Solid Tumors; Mucoepidermal Carcinoma (MEC) of the Salivary Gland; Pigmented Villo-nodular Synovitis (PVNS); Gastrointestinal Stromal Tumors (GIST); Anaplastic Thyroid Carcinoma (ATC); Solid Tumors With Documented Malignant Pleural or Peritoneal Effusions; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis Type I (NF-1); Melanoma; Schwannomatosis
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012 - Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Intervention: Drug: AS101
Sponsors: BioMAS Ltd; BioMAS Ltd
Not yet recruiting - verified June 2011 - Condition: Chronic Myelomonocytic Leukemia
Intervention:
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified January 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: sodium stibogluconate
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified October 2011 - Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Procedure: Autologous bone marrow transplantation; Procedure: Allogeneic bone marrow transplantation
Sponsors: Tehran University of Medical Sciences; Tehran University of Medical Sciences
Recruiting - verified July 2011 - Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: Irradiated haploidentical allogeneic lymphocytes; Radiation: total-body irradiation
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Hematologic Malignancy; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Hodgkin's Disease
Intervention: Drug: Ciclopirox Olamine
Sponsors: University Health Network, Toronto; University Health Network, Toronto; The Leukemia and Lymphoma Society
Recruiting - verified April 2012 - Conditions: Cancer; Myeloma; Multiple Myeloma
Intervention: Drug: Bortezomib
Sponsors: University of Utah; University of Utah; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia
Interventions: Biological: pretargeted radioimmunotherapy; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Radiation: total-body irradiation; Other: pharmacological study; Procedure: peripheral blood stem cell transplantation; Drug: fludarabine phosphate
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Acute Myeloid Leukemia; Lymphoblastic Leukemia; Acute Leukemia; Non Hodgkins Lymphoma; Chronic Myeloid Leukemia
Intervention: Radiation: Intensity modulated total marrow irradiation
Sponsors: University of Illinois; University of Illinois
Recruiting - verified August 2011 - Conditions: Aplastic Anemia; Leukemia; Myelodysplastic Syndrome
Intervention: Other: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine. CD34+ T-cell depleted peripheral blood stem cell transplant
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Children's Hospital Boston; Children's Hospital Medical Center, Cincinnati; Children's Hospital and Health System Foundation, Wisconsin; Rockefeller University; Fred Hutchinson Cancer Research Center
Recruiting - verified November 2011 - Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Interventions: Drug: Decitabine 5 mg/m2/day; Drug: Decitabine 7.5mg /m2/day; Drug: Decitabine 10 mg/m2/day
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Myelodysplastic Syndrome MDS
Interventions: Drug: Valproic aicd; Drug: Lenalidomide
Sponsors: Heinrich-Heine University, Duesseldorf; Heinrich-Heine University, Duesseldorf
Recruiting - verified June 2011 - Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Lymphomas; Bone Marrow Failure; Hemoglobinopathy; Immune Deficiency; Osteopetrosis
Intervention: Device: CliniMACS® (T cell depletion)
Sponsors: Carolinas Healthcare System; Andrew Gilman
Recruiting - verified April 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma; AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; HIV-associated Hodgkin Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Secondary Myelodysplastic Syndromes
Interventions: Procedure: leukapheresis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis; Other: DNA analysis; Other: RNA analysis; Other: flow cytometry; Other: reverse transcriptase-polymerase chain reaction; Other: nucleic acid sequencing; Other: protein expression analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Melanoma; Myelodysplastic Syndrome; Multiple Myeloma; Lymphoma
Intervention: Other: Tissue Registry Study
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute
Recruiting - verified July 2011 - Condition: Multiple Myeloma
Interventions: Procedure: Apheresis; Procedure: Stem Cell Transplantation; Drug: Melphalan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: trastuzumab; Drug: carboplatin; Drug: docetaxel; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Myelodysplastic Syndromes; Thrombocytopenia
Intervention: Drug: Eltrombopag
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2012 - Conditions: Hematologic Diseases; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: Ondansetron; Drug: Aprepitant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Condition: Myeloproliferative Neoplasms
Intervention: Drug: Pomalidomide
Sponsors: University of Ulm; University of Ulm
Recruiting - verified November 2011 - Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Drug: Vorinostat; Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified March 2012 - Conditions: Leukemia; Myelodysplastic Syndrome; Multiple Myeloma; Lymphoma
Interventions: Drug: Fludarabine-Melphalan & Rabbit antithymocyte globulin; Procedure: Stem Cell Transplant; Procedure: Stem Cells Collections
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2011 - Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: 3'-deoxy-3'-[18F]fluorothymidine
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Lymphoma; B-cell Lymphoma; Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia
Intervention: Drug: Bone marrow transplantation
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: Standard Therapy; Procedure: Local Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox; Drug: Deferasirox placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine; Drug: 5-Azacytidine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Giant Cell Tumor of Bone; Osteoclastoma
Intervention: Drug: Zoledronic acid
Sponsors: Leiden University Medical Center; Leiden University Medical Center
Recruiting - verified April 2012 - Conditions: Neurofibromatosis Type 1; Malignant Peripheral Nerve Sheath Tumor; Plexiform Neurofibroma; Optic Glioma; Neurofibroma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Other: biologic sample preservation procedure; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia, Acute Myelogenous (AML); Leukemia, Acute Lymphocytic (ALL); Leukemia, Chronic Myelogenous (CML); Myelodysplastic Syndrome (MDS); Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: WT1 Peptide-Pulsed Dendritic Cells; Drug: Donor Lymphocytes; Drug: IL-4; Drug: KLH; Drug: WT1 Peptides; Drug: Endotoxin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Nonmalignant Neoplasm
Interventions: Procedure: umbilical cord blood transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic bone marrow transplantation; Drug: fludarabine phosphate; Drug: treosulfan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: methotrexate; Drug: cyclosporine; Drug: mycophenolate mofetil; Genetic: DNA analysis; Other: laboratory biomarker analysis; Genetic: cytogenetic analysis; Biological: anti-thymocyte globulin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); medac GmbH
Recruiting - verified April 2012 - Conditions: Myelodysplastic Syndromes; Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine; Drug: Lenalidomide
Sponsors: Dresden University of Technology; Dresden University of Technology; Celgene Corporation
Recruiting - verified June 2011 - Conditions: MonoMAC; Myelodysplastic Syndrome; Immunodeficiency
Interventions: Procedure: Reduced-Intensity Hematopoietic Stem Cell; Drug: Fludarabine; Procedure: Total Body Irradiation (TBI); Drug: Filgrastim; Drug: Sirolimus; Drug: Tacrolimus; Drug: Ursodiol
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Bone Metastases
Intervention: Device: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Sponsors: American College of Radiology - Image Metrix; American College of Radiology - Image Metrix; Academy of Molecular Imaging
Recruiting - verified June 2011 - Conditions: Acute Myeloid Leukemia; Infantile Leukemia (Both AML and ALL); Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasms; Biphenotypic Leukemia
Interventions: Drug: Sorafenib; Drug: Cytarabine; Drug: Clofarabine
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified December 2011 - Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome
Interventions: Drug: MLN4924; Drug: MLN4924 and azacitidine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Hematological Malignancy; Bone Marrow Failure Syndrome
Interventions: Drug: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders; Radiation: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders; Procedure: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011 - Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Mycoses; Sezary Syndrome; Lymphoma, T-Cell, Cutaneous; Bone Marrow Transplant Failure; Lymphoma, Non-Hodgkin; Cutaneous T-cell Lymphoma of Skin
Interventions: Drug: anti-thymocyte globulin; Drug: cyclosporine
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011 - Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Decitabine; Drug: Clofarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genzyme
Recruiting - verified February 2012 - Conditions: Leukemia; Lymphoma; Multiple Myeloma; Plasma Cell Neoplasm; Myelodysplastic Syndromes
Intervention: Biological: human myeloid progenitor cells
Sponsors: Cellerant Therapeutics; Cellerant Therapeutics; Department of Health and Human Services
Recruiting - verified November 2011 - Conditions: Fever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neutropenia; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Biological: recombinant human mannose-binding lectin
Sponsors: National Cancer Institute (NCI); Enzon Pharmaceuticals, Inc.; National Cancer Institute (NCI)
Recruiting - verified August 2007 - Conditions: Leukemia; AML; MDS
Intervention: Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
Intervention: Drug: Lenalidomide
Sponsors: Groupe Francophone des Myelodysplasies; Groupe Francophone des Myelodysplasies; Celgene Corporation
Recruiting - verified February 2010 - Conditions: Neuroblastoma; Bone Marrow, Sympathetic Nervous System
Intervention: Other: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011 - Condition: Bone Neoplasm
Interventions: Device: Bioactive glass granules (Bonalive); Device: Beeta-tricalcium phosphate (ChronOs); Procedure: Autograft; Procedure: Allograft (frozen femoral head)
Sponsors: Turku University Hospital; Turku University Hospital
Recruiting - verified June 2011 - Conditions: Brain Tumors and /or Solid Tumors Including:; Brain Stem Glioma; High Grade CNS Tumors; Ependymoma; Medulloblastoma; Craniopharyngioma; Low Grade CNS Tumors; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Ewing Sarcoma; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Other
Intervention: Drug: Methionine
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Conditions: Leukemia; Lymphoma, Non-Hodgkin; Hodgkin Disease; Myelodysplastic Syndromes; Multiple Myeloma
Interventions: Genetic: CD34-TK75 transduced donor lymphocytes; Radiation: Sub Study using 18 FHBG PET/CT Scans
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified March 2012 - Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance StudyCondition: Breast Cancer
Intervention:
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified August 2011 - Conditions: Chronic Myeloproliferative Disorders; Fanconi Anemia; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Paroxysmal Nocturnal Hemoglobinuria
Interventions: Biological: anti-thymocyte globulin; Biological: graft-versus-tumor induction therapy; Drug: fludarabine phosphate; Drug: melphalan; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Conditions: Leukemia, Myeloid, Acute; Acute Lymphoblastic Leukemia; Myelodysplasia; Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin
Intervention: Drug: Sitagliptin
Sponsors: Indiana University; Indiana University School of Medicine
Recruiting - verified May 2012 - Conditions: Neoplasms; Bone Metastases
Intervention: Biological: Anti-NGF AB
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Myelodysplastic Syndrome
Intervention: Drug: Lenalidomide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012 - Conditions: MDS; AML; ALL; BAL
Intervention: Drug: Clofarabine in combination with IV busulfan and ATG
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified August 2011 - Conditions: Multiple Myeloma; End Stage Renal Disease
Interventions: Drug: Cyclophosphamide, anti-thymocyte globulin, cyclosporine; Procedure: Kidney transplant; Radiation: Thymic irradiation; Procedure: Bone marrow transplant from a related donor
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: treosulfan; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: peripheral blood stem cell transplantation; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2012 - Conditions: Stem Cell Transplantation; Leukemia; Lymphoma
Interventions: Drug: Thiotepa; Drug: Clofarabine; Drug: Busulfan; Procedure: Allogeneic Stem Cell Transplantation; Drug: Thymoglobulin (ATG); Drug: G-CSF (Filgrastim)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute; Leukemia, Myelocytic, Chronic
Interventions: Other: Allogeneic Lymphocytes; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Methylprednisolone; Drug: Cyclosporine
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Condition: Neurofibromatosis Type 1
Interventions: Drug: Lovastatin ™; Device: placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Children's Hospital Boston; Children's Hospital Philadelphia; Children's Research Institute; Children's Hospital Medical Center, Cincinnati; National Cancer Institute (NCI); University of Chicago; University of Utah; Washington University School of Medicine; The Children's Hospital at Westmead
Recruiting - verified July 2011 - Conditions: Acute Myelocytic Leukemia; Acute Lymphocytic Leukemia; Chronic Myelocytic Leukemia; Chronic Lymphocytic Leukemia; Myelodysplastic Syndromes
Intervention: Drug: ON 01910.Na
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.
Recruiting - verified January 2012 - Condition: Hematopoietic/Lymphoid Cancer
Interventions: Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: stress management therapy; Procedure: support group therapy
Sponsors: National Cancer Institute (NCI); University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting - verified January 2009 - Condition: Prostate Cancer
Intervention: Drug: TK1258
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Myelodysplastic Syndrome With Isolated Del(5q); Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Drug: lenalidomide; Biological: bystander vaccine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified February 2012 - Condition: Cancer
Interventions: Drug: hydroxychloroquine; Drug: sunitinib malate
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: National Cancer Institute (NCI); Asan Medical Center
Recruiting - verified July 2009 - Condition: Sarcoma
Intervention: Drug: dacarbazine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified December 2011 - Condition: Myelodysplastic Syndromes
Intervention: Drug: Lenalidomide, Decitabine
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified February 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: bortezomib; Drug: vorinostat
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Merck; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Chronic Myelogenous Leukemia
Intervention: Other: Chart Review
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Pancreatic Head Mass
Intervention: Procedure: Transgastric diagnostic endoscopic peritoneoscopy
Sponsors: Ohio State University; Jeffrey Hazey; Natural Orifice Surgery Consortium for Assessment and Research
Recruiting - verified May 2012 - Conditions: Smouldering Systemic Mastocytosis; Indolent Systemic Mastocytosis; Cutaneous Mastocytosis With Handicap; Mastocytosis
Interventions: Drug: masitinib (AB1010); Drug: placebo
Sponsors: AB Science; AB Science
Recruiting - verified January 2012 - Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)Conditions: Stem Cell Transplantation; Leukemia
Interventions: Drug: Fludarabine; Drug: Busulfan; Drug: Thymoglobulin; Drug: Azacitidine; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Cervical Cancer; Endometrial Cancer; Vaginal Cancer
Intervention: Procedure: CT or MRI + Blood Test
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: SKI-606 (Bosutinib)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: nilotinib; Genetic: cytogenetic analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); All Ireland Cooperative Oncology Research Group
Recruiting - verified January 2009 - Conditions: MDS; Leukemias; Lymphomas
Intervention: Drug: Drug: busulfan, Cyclophosphamide, Total Body Irradiation
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Otsuka Pharmaceutical Co., Ltd.; National Center for Research Resources (NCRR)
Recruiting - verified January 2012 - Condition: Chronic Myelogenous Leukemia
Interventions: Drug: nilotinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic Syndrome With Isolated Del(5q); Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: fludarabine phosphate; Drug: treosulfan; Radiation: total-body irradiation; Procedure: umbilical cord blood transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndrome With Isolated Del(5q); Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Peripheral T-cell Lymphoma; Plasma Cell Neoplasm; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: mycophenolate mofetil; Drug: tacrolimus; Radiation: total-body irradiation; Procedure: allogeneic bone marrow transplantation; Biological: natural killer cell therapy; Genetic: fluorescence in situ hybridization; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Osteosarcoma
Interventions: Drug: Saracatinib; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Progressive Sarcoma
Intervention: Drug: Everolimus/RAD001
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: CHRONIC MYELOGENOUS LEUKEMIA
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: educational intervention
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Myelodysplastic Syndrome; Non-Hodgkins Lymphoma; Chronic Myelogenous Leukemia
Intervention: Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Childhood Anaplastic Large Cell Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Chronic Lymphocytic Leukemia; Refractory Cytopenia With Multilineage Dysplasia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Conditions: Lung or Prostatic Neoplasms; Colorectal or Kidney Neoplasms; Pancreatic Neoplasms; Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive; Melanoma; CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Condition: Osteosarcoma
Interventions: Drug: Zoledronic acid; Drug: Standard chemotherapy
Sponsors: Tata Memorial Hospital; Tata Memorial Hospital
Recruiting - verified June 2011 - Condition: Osteosarcoma
Intervention:
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified January 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: mycophenolate mofetil; Radiation: total-body irradiation; Procedure: umbilical cord blood transplantation; Drug: cyclosporine; Procedure: double-unit umbilical cord blood transplantation; Other: laboratory biomarker analysis; Procedure: biopsy; Other: immunologic technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Osteosarcoma
Interventions: Dietary Supplement: Curcumin powder; Dietary Supplement: Ashwagandha extract
Sponsors: Tata Memorial Hospital; Tata Memorial Hospital; Pharmanza Herbals Pvt Limited (PHPL)
Recruiting - verified June 2011 - Conditions: Advanced Cancer; Bone Metastases
Interventions: Procedure: Laser Ablation; Procedure: Magnetic Resonance Thermal Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; BioTex, Inc.
Recruiting - verified January 2012 - Conditions: Cancer; GCT; Giant Cell Tumor of Bone; Benign GCT
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Conditions: Cancer; Pain
Intervention: Behavioral: PRO-SELF PLUS Pain Management Program
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012 - Conditions: Non-Hodgkin's Lymphoma; Leukemia; Multiple Myeloma; Myeloproliferative Disorder
Interventions: Biological: thymoglobulin; Biological: thymoglobulin
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; Genzyme
Recruiting - verified January 2012 - Conditions: Polycythemia Vera; Essential Thrombocythemia; Myelofibrosis
Intervention:
Sponsors: University of Utah; University of Utah; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Osteosarcoma; Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions: Biological: Bevacizumab; Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genentech; National Institutes of Health (NIH)
Recruiting - verified June 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Relapsing Chronic Myelogenous Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: nilotinib; Drug: imatinib mesylate; Other: pharmacological study; Genetic: polymerase chain reaction
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Acute Lymphocytic Leukemia; Relapsed/Refractory Chronic Lymphocytic Leukemia; Relapsed/Refractory Non Hodgkin's Lymphoma; Hodgkins Disease; Relapsed Refractory Multiple Myeloma
Interventions: Drug: Antithymocyte Globulin; Drug: Clofarabine; Drug: Clofarabine; Drug: Clofarabine
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Genzyme
Recruiting - verified February 2012 - Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Interventions: Drug: LBH589; Drug: Decitabine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Condition: Myelogenous Leukemia, Chronic
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Bone Metastases; Multiple Myeloma
Interventions: Device: ExAblate 2000; Device: Sham
Sponsors: InSightec; InSightec
Recruiting - verified October 2011 - Conditions: Acute Myelogenous Leukemia; Lymphoid Leukemia; Chronic Myelogenous Leukemia; Malignant Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia; Myeloproliferative Disorder; Anemia, Aplastic; Myelodysplastic Syndromes
Interventions: Drug: Fludarabine; Drug: Melphalan; Drug: Stem cells; Drug: Campath
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2011 - Condition: Leukemia
Interventions: Drug: imatinib mesylate; Drug: panobinostat; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: MDS; Anemia, Aplastic; Inborn Errors of Metabolism; Congenital Marrow Failure; Congenital Immunodeficiency Syndrome
Intervention: Biological: ALDHbr Umbilical Cord Blood Cells
Sponsors: Duke University; Duke University; Aldagen
Recruiting - verified August 2011 - Conditions: Neurofibromatosis Type 1; Plexiform Neurofibroma
Intervention: Drug: PEG-interferon alfa-2b
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Acute Myelogenous Leukemia (AML); Chronic Myelogenous Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndrome (MDS); B Cell Malignancies
Intervention: Biological: WT1 derived peptides
Sponsors: Duke University; Duke University
Recruiting - verified January 2012 - Conditions: Leukemia; Lymphoma; Bone Marrow Failure; Immunodeficiencies; Histiocytosis
Interventions: Drug: Full Intensity with TBI; Drug: Full Intensity; Drug: Reduced Intensity; Drug: Reduced Intensity (Fanconi)
Sponsors: New York Medical College; New York Medical College
Recruiting - verified April 2012 - Conditions: Leukemia; Lymphoma; Multiple Myeloma; Aplastic Anemia
Interventions: Biological: Umbilical Cord Blood Transplantation After Myeloablative Conditioning; Biological: Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified May 2012 - Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); Actinium Pharmaceuticals
Recruiting - verified January 2012 - Conditions: Solid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Ovarian Mixed Germ Cell Tumor; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Neuroblastoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan; Drug: melphalan; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation; Other: pharmacological study; Procedure: autologous bone marrow transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011 - Conditions: Haemoglobinopathies,; Myelodysplastic Syndromes,; Other Inherited or Acquired Anaemia (e.g. MPD, Diamond-blackfan Anaemia and Other Rare Anaemias),; Transfusional Iron Overload
Intervention: Drug: deferasirox
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Interventions: Other: NK Cell Infusion; Biological: Immunotherapy; Device: Miltenyi Biotec CliniMACS device; Drug: Interleukin-2 (IL-2); Drug: Clofarabine; Drug: Cyclophosphamide; Drug: Etoposide
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified December 2011 - Conditions: Myeloproliferative Disease; Myelofibrosis; Idiopathic Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention:
Sponsors: Myeloproliferative Disorders-Research Consortium; Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2012 - Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Interventions: Drug: Idarubicin; Drug: Cytarabine; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified April 2012 - Conditions: Soft Tissue Sarcoma; Osteosarcoma
Intervention:
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Huntsman Cancer Institute
Recruiting - verified August 2010 - Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: paricalcitol; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: dual x-ray absorptometry; Procedure: quality-of-life assessment
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified October 2010 - Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Acute, T-Cell; Juvenile Myelomonocytic Leukemia Lymphoblastic; T-cell Lymphoblastic Lymphoma; Myelodysplastic Syndrome
Interventions: Procedure: Haploidentical donor derived natural killer cell infusion; Drug: Chemotherapy (Cyclophosphamide, Fludarabine, Interleukin-2, Mesna); Device: CliniMACS
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Assisi Foundation
Recruiting - verified March 2012 - Conditions: Pain; Bone Metastasis
Interventions: Radiation: Radiotherapy; Radiation: Radiotherapy; Radiation: Radiotherapy; Radiation: Radiotherapy
Sponsors: International Atomic Energy Agency; International Atomic Energy Agency
Recruiting - verified October 2011 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: busulfan; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Baylor College of Medicine
Recruiting - verified June 2009 - Condition: Bone Tumors
Intervention: Device: Cone Beam CT Scan
Sponsors: University of Rochester; University of Rochester; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Conditions: Neurofibromatosis Type 1; Reading Disabilities
Interventions: Behavioral: Tutoring Program I; Behavioral: Tutoring Program II
Sponsors: Vanderbilt University; Vanderbilt University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2011 - Condition: Hematologic Neoplasms
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified October 2011 - Condition: Osteosarcoma
Intervention: Biological: Tissue Procurement
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Hospital for Special Surgery, New York
Recruiting - verified October 2011 - Conditions: Non-rhabdomyosarcoma Soft Tissue Sarcoma; Bone Sarcoma
Intervention: Radiation: Proton Beam Radiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Brigham and Women's Hospital; Children's Hospital Boston; Dana-Farber Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified September 2011 - Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Biological: WT1-sensitized T cells
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Condition: Cancer
Interventions: Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: immunological diagnostic method; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Baylor College of Medicine
Recruiting - verified June 2009 - Conditions: Acute Myeloid Leukemia; Advanced Myelodysplastic Syndromes
Intervention: Drug: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011 - Conditions: Breast Cancer; Bone Metastases
Interventions: Drug: Dasatinib; Drug: Zoledronic Acid
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2012 - Conditions: Hodgkin's Disease; Non Hodgkin's Lymphoma; Myeloma; Leukemia; Myelodysplasia
Intervention: Drug: Non-myeloablative Stem Cell Transplantation
Sponsors: Duke University; Duke University
Recruiting - verified February 2012 - Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplasia; Chronic Myeloid Leukemia
Interventions: Radiation: Total Body Irradiation; Drug: Thiotepa; Drug: Fludarabine; Biological: Rabbit ATG; Drug: Palifermin
Sponsors: Indiana University; Indiana University
Recruiting - verified January 2012 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Radiation: total-body irradiation; Radiation: iodine I 131 monoclonal antibody BC8; Procedure: allogeneic bone marrow transplantation; Drug: tacrolimus; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Myelodysplastic Syndromes
Intervention:
Sponsors: Radboud University; Radboud University
Recruiting - verified July 2011 - Conditions: Hematologic Malignancy; MDS; Aplastic Anemia
Intervention: Procedure: haplo/cord transplant
Sponsors: Duke University; Duke University; Miltenyi Biotec GmbH
Recruiting - verified August 2011 - Conditions: Cancer; Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Interventions: Drug: Fludarabine, Cyclophosphamide; Procedure: Transplantation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Conditions: Myelodysplastic Syndrome (MDS); Severe Aplastic Anemia (SAA)
Interventions: Other: Umbilical Cord Blood; Other: Haploidentical Stem Cells; Device: Miltenvi CliniMACs CD34 Reagent System
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified October 2011 - Condition: Neoplasms
Intervention: Other: buccal swabs and obtaining peripheral blood
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); American Cancer Society
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Intervention: Drug: Zoledronic acid
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Brigham and Women's Hospital; Dana-Farber Cancer Institute; American Society of Clinical Oncology
Recruiting - verified July 2011 - Conditions: Leukemia; Bone Marrow Transplantation; Immunodeficiencies
Intervention: Device: CliniMACs
Sponsors: Children's Hospital of Philadelphia; Children's Hospital of Philadelphia
Recruiting - verified June 2011 - Condition: Acute Myeloid Leukemia
Interventions: Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: Sapacitabine; Drug: sapacitabine
Sponsors: Cyclacel Pharmaceuticals, Inc.; Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes
Interventions: Drug: ABT-888; Drug: topotecan hydrochloride; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Leukemia; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Myeloproliferative Disorders
Interventions: Drug: Ara C; Drug: Cyclophosphamide; Drug: MESNA; Procedure: TBI; Biological: Campath-1h; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified April 2012 - Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoid; Myelodysplastic Syndromes; Leukemia, Myelogenous, Chronic
Intervention: Device: CliniMACS CD34 Reagent System
Sponsors: Indiana University; Indiana University School of Medicine
Recruiting - verified January 2012 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: PEG-IFN-a2a
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified August 2011 - Conditions: Leukemia, Acute Lymphocytic (ALL); Leukemia, Myeloid, Acute(AML); Leukemia, Myeloid, Chronic(CML); Juvenile Myelomonocytic Leukemia (JMML); Hemoglobinuria, Paroxysmal Nocturnal (PNH); Hodgkin Lymphoma; Lymphoma, Non-Hodgkin (NHL); Myelodysplastic Syndrome (MDS)
Interventions: Device: CliniMACS; Procedure: Stem cell transplantation; Drug: Systemic chemotherapy and antibodies
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012 - Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: intensity-modulated radiation therapy
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: lapatinib ditosylate; Genetic: gene expression analysis; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified July 2009 - Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Intervention: Biological: donor lymphocytes
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012 - Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease
Intervention: Procedure: Cytogenetic Analysis of Bone Marrow Specimen
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Recruiting - verified April 2012 - Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Bone Metastases
Intervention: Procedure: Biological imaging guided antalgic radiotherapy
Sponsors: University Hospital, Ghent; University Hospital, Ghent
Recruiting - verified August 2011 - Conditions: Myelodysplastic Syndrome; Hodgkin's Lymphoma; Non-Hodgkin's Disease; Acute Leukemia; Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Biological: rituximab; Drug: Methotrexate; Drug: Sirolimus; Drug: Cyclosporine; Drug: Doxorubicin hydrochloride; Drug: Etoposide; Drug: Fludarabine phosphate; Drug: Prednisone; Drug: Vincristine sulfate; Drug: Cytarabine; Drug: Tacrolimus; Biological: Alemtuzumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: etoposide; Drug: methotrexate; Drug: rasburicase; Drug: sirolimus; Drug: tacrolimus; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunologic technique; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital
Recruiting - verified April 2008 - Conditions: Hypopituitarism; Hypogonadism; Thyroid Dysfunction; Bone Diseases, Metabolic
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012 - Conditions: Lymphoma; Bone Marrow Transplantation
Interventions: Drug: Fludarabine; Drug: Melphalan; Procedure: Allogeneic Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Dyskeratosis Congenita; Fanconi Anemia; Myelodysplastic Syndromes; Nonmalignant Neoplasm; Pearson Marrow-pancreas Syndrome; Shwachman-diamond Syndrome
Interventions: Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunologic technique; Procedure: biopsy
Sponsors: University Hospital Freiburg; University Hospital Freiburg
Recruiting - verified December 2011 - Conditions: Myelodysplastic Syndrome; Leukemia
Interventions: Procedure: Cord Blood Infusion; Drug: Busulfan; Drug: Fludarabine; Drug: Rituximab; Other: ATG; Drug: Cyclophosphamide; Drug: Clofarabine; Radiation: Total Body Irradiation (TBI); Drug: Melphalan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Azacitidine; Drug: Beta Erythropoietin
Sponsors: PETHEMA Foundation; PETHEMA Foundation; Roche Pharma AG; Celgene Corporation
Recruiting - verified December 2011 - Condition: Exostoses, Multiple Hereditary
Intervention:
Sponsors: University of British Columbia; University of British Columbia; MHE Coalition
Recruiting - verified October 2011 - Condition: Exostoses, Multiple Hereditary
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified October 2011 - Conditions: Breast Cancer; Hypercalcemia of Malignancy; Metastatic Cancer; Musculoskeletal Complications; Pain
Interventions: Drug: zoledronic acid; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); University of Leeds
Recruiting - verified November 2007 - Conditions: Graft Versus Host Disease; Infection; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: polymerase chain reaction; Other: bronchoalveolar lavage; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy; Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); St. Bartholomew's Hospital
Recruiting - verified September 2007 - Condition: Leukemia
Interventions: Biological: bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine; Biological: sargramostim
Sponsors: National Cancer Institute (NCI); Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified November 2008 - Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Non Hodgkin's Lymphoma; Hodgkin's Disease; Myelodysplastic Syndrome; Multiple Myeloma
Intervention: Biological: infusion of allogeneic CIK cells
Sponsors: Singapore General Hospital; Singapore General Hospital; National Medical Research Council (NMRC), Singapore
Recruiting - verified May 2012 - Condition: Bone Cysts
Interventions: Drug: I-040302; Other: Standard of Care
Sponsors: Kuros Biosurgery AG; Kuros Biosurgery AG
Not yet recruiting - verified March 2012 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012 - Conditions: Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Acute Myeloid Leukemia in Remission; Childhood Myelodysplastic Syndromes; de Novo Myelodysplastic Syndromes; Fanconi Anemia; Previously Treated Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Radiation: total-body irradiation; Procedure: allogeneic bone marrow transplantation; Drug: mycophenolate mofetil; Drug: cyclosporine; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab; Drug: arsenic trioxide; Drug: azacitidine; Drug: busulfan; Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: fludarabine phosphate; Drug: gemtuzumab ozogamicin; Drug: melphalan; Drug: tipifarnib; Genetic: DNA methylation analysis; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Other: diagnostic laboratory biomarker analysis; Other: immunologic technique; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); The University of New South Wales
Recruiting - verified August 2008 - Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009 - Condition: Myeloid Leukemia, Chronic
Intervention:
Sponsors: Dresden University of Technology; Dresden University of Technology; Medical Academy of Wroclaw, Poland; University of Leiden, Netherlands; Nordic Pediatric Hematology Oncology Group, Scandinavia; Uniuversity of Genua, Italy
Recruiting - verified February 2012 - Conditions: Acute Lymphoblastic Leukemia; Acute Myeloblastic Leukemia; Chronic Myeloid Leukemia
Intervention: Procedure: Blood test
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified August 2011 - Conditions: Osteoarthritis; Osteosarcoma; Scoliosis; Cerebral Palsy
Intervention:
Sponsors: University of Florida; University of Florida
Recruiting - verified April 2012 - Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Secondary Myelofibrosis
Interventions: Drug: Busulfan; Drug: Cytarabine; Drug: Fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: tamoxifen; Drug: triptorelin; Drug: letrozole; Drug: zoledronic acid
Sponsors: National Cancer Institute, Naples; National Cancer Institute, Naples; Second University of Naples
Recruiting - verified October 2011 - Conditions: Myelodysplastic Syndrome; Leukemia
Interventions: Drug: Thymoglobulin; Drug: Busulfan; Drug: Fludarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Paroxysmal Nocturnal Hemoglobinuria; Philadelphia Chromosome Negative Chronic Myelogenous Leukemia; Polycythemia Vera; Primary Myelofibrosis; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Radiation: total-body irradiation; Drug: fludarabine phosphate; Procedure: peripheral blood stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: polymerase chain reaction; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012 - Conditions: Chronic Myelogenous Leukemia; Acute Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome
Intervention: Device: Miltenyi CliniMACS CD34 Reagent System
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011 - Condition: Leukemia
Interventions: Biological: GM-K562 cell vaccine; Biological: recombinant interferon alfa; Biological: sargramostim
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Neoplasms
Intervention: Procedure: Biopsies for tissue and blood collection
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: melphalan; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011 - Conditions: Hematologic Neoplasms; Neural Tube Defects; Myeloproliferative Disorders
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: Sirolimus
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: ex-vivo umbilical cord blood expansion; Procedure: double-unit umbilical cord blood transplantation; Procedure: biopsy; Other: immunologic technique; Other: diagnostic laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Breast Cancer; Osteoporosis
Interventions: Drug: risedronate sodium; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); International Breast Cancer Study Group
Recruiting - verified May 2007 - Conditions: Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelofibrosis; MDS; Refractory Anemia; Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Multiple Myeloma; Non-Hodgkin's Lymphoma; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Conditions: Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: stem cell transplantation; Radiation: total-body irradiation; Drug: methylprednisolone; Drug: allopurinol; Drug: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Conditions: Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011 - Conditions: Anemia; Cardiovascular Complications; Hot Flashes; Osteoporosis; Prostate Cancer
Interventions: Drug: releasing hormone agonist therapy; Drug: transdermal estrogen
Sponsors: National Cancer Institute (NCI); Imperial College London
Recruiting - verified June 2008 - Conditions: Neurofibromatosis Type 1; Sarcoma
Interventions: Biological: filgrastim; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia
Intervention: Drug: Clofarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genzyme
Recruiting - verified February 2012 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib (BMS-354825)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified April 2012 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: Total Body Irradiation (TBI); Drug: Granulocyte colony-stimulating factor (G-CSF); Drug: Phenytoin; Drug: Methotrexate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Sarcoma, Ewing's; Rhabdomyosarcoma; Soft Tissue Sarcoma; Musculoskeletal Tumors
Intervention: Procedure: Delivery of conformal limited margin radiotherapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Lance Armstrong Foundation
Recruiting - verified October 2011 - Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With OsteosarcomaCondition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011 - Condition: Hematologic Malignancies
Intervention: Drug: Granulocyte Colony Stimulating Factor
Sponsors: Emory University; Emory University
Recruiting - verified November 2011 - Conditions: Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Myeloproliferative Disorders; Blood Cancer; Myelodysplastic Syndromes
Interventions: Procedure: Total Lymphoid Irradiation (TLI); Procedure: Anti-Thymocyte Globulin as Conditioning
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Conditions: Leukemia, Myeloid, Chronic; AML; Leukemia, Lymphocytic, Acute; MDS; Leukemia, Lymphocytic, Chronic; JMML; Hodgkin's Disease; Non-hodgkin's Lymphoma; Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant; Drug: Cyclophosphamide; Radiation: Total Body Irradiation; Drug: Busulfan
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Leukemia; Lymphoma; Hematologic Diseases
Intervention: Procedure: collection and storage of tissue samples for research
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Leukemia, Myeloid, Chronic; Lymphomas; Multiple Myeloma; Myelodysplastic Syndrome; Leukemia, Lymphocytic, Acute; Leukemia, Lymphocytic, Chronic; AML
Interventions: Procedure: Donor Lymphocyte Infusion; Drug: Induction Chemotherapy + DLI
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: Alemtuzumab (Campath)
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Conditions: Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia
Intervention:
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Recruiting - verified June 2011 - Conditions: Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Myelodysplasia; Chronic Myeloid Leukemia; Histiocytosis
Interventions: Drug: Chemotherapy and antibodies; Device: Miltenyi Biotec CliniMACS; Procedure: Allogeneic stem cell transplantation
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified December 2011 - Condition: Juvenile Myelomonocytic Leukemia
Intervention: Procedure: Stem Cell Transplant
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011 - Condition: Leukemia, Myelogenous, Chronic
Intervention: Drug: Nilotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified January 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Radiation: iodine I 131 monoclonal antibody BC8; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Primary CNS Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; HIV Infection; HIV-associated Hodgkin Lymphoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Central Nervous System Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Neurofibromatosis Type I
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified January 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Biological: therapeutic allogeneic lymphocytes; Drug: mycophenolate mofetil; Drug: cyclosporine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: bone marrow aspiration; Procedure: peripheral blood stem cell transplantation; Genetic: polymerase chain reaction; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Childhood Langerhans Cell Histiocytosis; Fanconi Anemia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: melphalan; Drug: methylprednisolone; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Milton S. Hershey Medical Center
Recruiting - verified October 2008 - Conditions: Metastatic Cancer; Pain
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Trans-Tasman Radiation Oncology Group (TROG); Cancer Research UK; Dutch Bone Metastasis Study Group; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011 - Conditions: Neoplasms; Hematologic Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Autosomal Recessive Polycystic Kidney Disease; Congenital Hepatic Fibrosis; Caroli's Disease; Polycystic Kidney Disease; Joubert Syndrome; Cerebro-Oculo-Renal Syndromes; COACH Syndrome; Senior-Loken Syndrome; Dekaban-Arima Syndrome; Cogan Oculomotor Apraxia; Nephronophthisis; Bardet-Biedl Syndrome; Alstrom Syndrome; Oral-Facial-Digital Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Biological: recombinant interferon alfa; Drug: cytarabine; Drug: hydroxyurea; Drug: imatinib mesylate; Procedure: allogeneic bone marrow transplantation; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); III. Medizinische Klinik Mannheim
Recruiting - verified November 2011 - Condition: Mastocytosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Adult Acute Lymphoblastic Leukemia in Remission; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Relapsing Chronic Myelogenous Leukemia
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: imatinib mesylate; Drug: dasatinib; Drug: nilotinib; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: fludarabine phosphate; Procedure: peripheral blood stem cell transplantation; Biological: therapeutic allogeneic lymphocytes; Genetic: polymerase chain reaction; Other: flow cytometry; Genetic: fluorescence in situ hybridization; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Fanconi's Anemia; Anemia, Diamond Blackfan; Dyskeratosis Congenital; Thrombocytopenia; Neutropenia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011 - Conditions: Adult Langerhans Cell Histiocytosis; Childhood Langerhans Cell Histiocytosis; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2007 - Conditions: HIV Infection; Kaposi's Sarcoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Neuroblastoma
Interventions: Drug: buthionine sulfoximine; Drug: melphalan; Procedure: Peripheral blood stem cell infusion; Other: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Acromegaly; Pituitary Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2012 - Conditions: Ewing's Sarcoma; Leukemia; Lymphoma; Neoplasm; Sarcoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Abnormalities; Craniopharyngioma; Cushing's Syndrome; Endocrine Disease; Pituitary Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011 - Conditions: Graft vs Host Disease; Hematologic Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011 - Conditions: Hematologic Disease; Hematologic Neoplasm; Pancytopenia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: Communicable Disease; Immunologic Deficiency Syndrome; Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Cockayne Syndrome; Skin Neoplasm; Xeroderma Pigmentosum
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: thiotepa; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified December 2011 - Conditions: Growth Disorder; Mental Retardation; Multiple Abnormalies
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified February 2012
 |
Join Clinical Trials That Study Bone Cancer |
